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The world of natural products has a long rich history dating back thousands of years and 
was the origin of medicine as we know it. Advancements in the field of natural products can be 
seen not only in the isolation of new molecules, but also in the advancement of new tools that are 
used to elucidate the structure of new compounds, identify lead compounds, as well as monitor 
the pharmokinetics of bioactive substances. The third chapter in this dissertation introduces a 
new tool that could be used in the later steps of drug development by being able to rapidly 
quantify a fluorinated compound in complex mixtures, the fourth chapter includes a comparison 
of an advanced spheroid bioassay with the traditional 2D assay that can be used to identify 
appropriate lead compounds, and the fifth chapter reveals techniques for applying natural 
products to a less discussed target: agricultural fungicides.  
Chapter 3 shows method optimization of quantitative 19F NMR for the rapid analysis of 
fluorinated compounds in complex mixtures without the need for an internal standard such as a 
deuterated solvent. The resulting method was validated with percent errors below 4% on two 
different instruments. Future work on this work be to use it for pharmokinetics in biological sera 
or to help determine the bioavailbility of compounds in complex biological matricies.  
Chapter 4 includes the isolation of polyketides that were tested against both monolayer 
and spheroid models of pancreatic cancer. The advanced in vitro spheroid technique shows how 
a compound (Asteltoxin G) that does not exhibit the most favorable activity on a monolayer 
assay can have high selectivity against pancreatic tumor cell line when the cells mimic a more 
tumor-like atmosphere with higher cell-cell interactions, core hypoxia, and a more hydrophobic 





Chapter 5 includes the isolation of three elsinochromes and a cyclic peptide with two 
analogs from a unique source: the endophytic fungus Spaceloma corylii. Two of the cyclic 
peptides had antifungal properties and were further explored for agriculturalapplications, a target 
less often analyzed in traditional academic research. These were tested both in vitro against 
possible pathogenic fungi and in vivo for systematic mobility was also analyzed and were found 
to be neither xylem nor phloem mobile. Additionally, due to the slow-growing nature of the 
fungus, growth conditions, and an isolation procedure was optimized. These optimizations 
compared variables such ad media components, media volumes, flask types, and methods of 





Chapter 1: Introduction 
1.1 What is a Natural Product? 
 Natural products, in their most general definition, are compounds produced by any living 
organisms with a molecular weight below 3000 Da.1 These compounds are further designated 
into two major categories: primary and secondary metabolites.1 Primary metabolites are 
compounds that are essential to a cell’s survival,1 such as lactic acid, amino acids, lipids and 
carbohydrates, while secondary metabolites are not used in the day-to-day function of cells,1 but 
may still contribute to the long-term survival of the organism. They can be relatively simple 
compounds like N-acyl L-homoserine lactones (AHLs),2 highly complex compounds like 
azadirachtin,3 or very large compounds like cyclosporine(Figure 1).4 
 
Figure 1. Diverse Secondary Natural Products 
Examples of natural products highlighting the diversity of functional groups that can be 





Typical uses for secondary metabolites vary tremendously, such as intracellular chemical 
signaling (e.g. hormones, quorum signaling or interkingdom signaling)5,6 as illustrated by 
melatonin and AHLs, and agents of chemical warfare as highlighted by compounds like 
microcystins found as the deadly compounds produced in blue-green algae blooms.7 In many 
cases, though, the full extent of the original intent of these secondary metabolites, as well as 
potential additional uses, remain undetermined.8,9  
 
1.2 Historic Examples of Natural Products and Their Users 
1.2.1 Ancient Times to Renaissance 
 Modern science has designated procedures to determine the activities of natural products, 
but humans have been utilizing experimentation to determine the effectiveness of natural 
products long before the advent of the scientific method.  One of the earliest examples of the 
implementation of natural products for medicinal purposes date back over 5300 years ago in the 
Alps.10 Along with the remains of the Hauslabojch mummy, also known as “Ötzi, the Ice Man,” 
were the fruiting bodies of the fungus Piptoporus betulinus, which have both antimicrobial and 
antitumoural properties.10 Such logic was not limited to a specific region or culture. In the 
ancient Greek and Roman Empires, a plant called silphium believed to belong to the genus 
Ferula,11 a genus of flowering plants belonging to the carrot, parsley, and celery family 
(Apiaceae), was used to treat a variety of ailments such as fever, warts, hair loss, and was most 
notably one of the most efficient abortifactants of the time. It was noted that feeding it to cattle 
bestowed a distinct flavor to the meat that made it even more of a prized commodity.12 This plant 






Figure 2. Examples Highlighting the Importance of Natural Products in Ancient Cultures. 
Coinage from the Mediterranean and phytoestrogens. A. Depiction of the silphium plant on 
coinage found in Cyrene highlighting the importance in ancient Mediterranean societies.13 B. A 
representation of the seed from the Silphium plant, believed to be the origination of the heart 
symbol that has persisted to modern day.14 The two compounds are phytoestrogens found in 
modern plants in the Apiaceae family known to target mammalian estrogen sensors.15 
 
Figure 2 is one of the few mechanisms scientist have had to determine the likely genus of 
the plant, because due to the popularity of the plant and the difficulty in culturing it, it quickly 
succumbed to extinction.12 It is believed the mechanism of action for the abortifactant is the high 
levels of phytoestrogens (plant derived compounds that mimic estrogen in mammals) that can 





This plant had also been identified in ancient Egyptian medicine, being in a nearby region 
and part of the Roman empire; however, Egypt had its own rich history with natural products. A 
document called the Ebers Papyrus was written in 2900 B.C. documenting over 700 natural 
product plant-based treatments including methods for their administrations.18 
During the Medieval period, medicinal inquiry was largely completed by monks with the 
focus of trying to understand how and why the human body succumbed to illness. For this 
reason, new sources of natural products were identified in the countryside, such as the juniper 
species, Juniperus sabina, as abortifactant, which also was theorized to work through 
phytoestrogens.11 Knowledge of these and other plants were usually passed on orally and so 
written records are scarce. As people emigrated from the countryside, however, many of these 
recipes were lost.11  
At the end of the medieval period, began the Renaissance. The Renaissance found 
scientists focused on the elements of science and medicine, both figuratively and literally. 
Antoine-Laurent de Lavoisier created the definition of an element with 55 substances listed as 
potential elements,19 while anatomy was advanced by human dissections, which helped 
diagnoses if not with novel medicines.20 The basis for the modern tools in natural products, the 
foundations of chemistry and anatomy were developed in this time. 
 
1.3 Advancements in the 19th-20th Centuries 
 Up until the 19th century, medicinal science focused on the describing either how the 
body ailed or what substances could be used to treat each ailment. That changed when a 
professor at the University of Dorpat in Estonia, Rudolf Buchheim, began to redefine the field of 




pharmacological agents and how they worked.21,22 His student, Oswald Schmiedeberg, is 
typically credited with the development of modern pharmacology due to the significant strides he 
made in defining the field and making Germany a leader in the pharmaceutical industry up until 
WWII.21,22 As synthetic chemistry was still in its infancy, (the first instance being the synthesis 
of urea in 182822) natural product isolation was the preferred method for obtaining many 
pharmacological agents. During the time between the mid-19th century to the mid-20th century, 
investigations of the pharmacological effects of natural products helped develop society’s 
understanding of medicine in leaps and bounds. Muscarine from the fly amanita fungus was 
found to effect electrical signaling in the heart, epinephrine was isolated from adrenal glands, 
histamine was isolated from pituitary gland extracts, pure insulin was isolated, and morphine was 
isolated from opium.22  
Another notable advancement occurred when Alexander Fleming left on vacation and 
returned to find the inhibition of bacterial growth on plates contaminated with Penicillium 
notatum in 1928.23,24 While unable to isolate the compound in large quantities himself, in 1940, 
two other scientists, Howard Florey and Ernst Chain, developed a mass production of the 
compound in time for WWII.24 All three scientists received the Nobel Prize in 1945 for the 
identification of a pharmacological agent that was able to target all gram-positive pathogens.24 
This began the antibiotic revolution, and it is estimated that penicillin and its derivatives have 
saved over 80 million lives.25,26 
Discoveries have continued throughout the mid-19th to mid-20th centuries with many new 
compounds being discovered from natural products that have been described as “truly 
revolutionary modern medicines with a tremendous impact upon healthcare.”27 For example, 




the rejection of organ transplants and the avermectins which nearly eliminated the African river 
blindness.27 However, natural products are still awaiting their next major revolution since the 
discovery of antibiotics. On the road to a new major revolution, there are some pitfalls that can 
delay bringing an extract to market. 
 
1.3.1 Pitfalls in Extracts to Market 
While natural products have had a profound impact on the current health system, there 
are some problems associated with natural product discovery that often cause delays in 
development. The most significant problems occur with the development of a majority of these 
natural products, which took 10-20 years to optimize, if the attempt was made to synthetically 
optimized their structures at all.27 There are four main reasons for the delay of a drug from 
discovery to a marketable product. The first is the formulation required. While all drugs require 
development time for formulations, some of these natural products pose challenges associated 
with their solubility and stability. The remaining three reasons are all present in the story of 
Taxol (paclitaxel): source/quantity of the original compound, synthetic reproduction, and 
biological target identification. Taxol was originally isolated from the bark of the Pacific yew 
tree, Taxus brevifolia,28 which is very slow-growing and harvesting the bark for Taxol results in 
tree mortality. Therefore, even after identifying its profound activity in extract form, sourcing 
enough compound for structure elucidation took 11 years.28  
Many of the same features that allow natural products to be selectively active targets, the 
most notable being chiral centers, are what cause problems in both the elucidation of the 
compound as well as the synthesis.  Natural products typically have more chiral centers than 




also much more difficult to produce in an efficient manner, sufficient quantity, and reasonable 
cost. Ultimately, a semisynthetic route was determined using an analogue from another yew tree, 
but this has been further replaced by being able to grow the plant cells independent of the tree, a 
feat highlighted in importance with award of a the Presidential Green Chemistry Challenge in 
2004.29–34 
The fourth reason for a delay in the development of natural products into a 
pharmaceutical agent is the final route to proving the effectiveness in a full system as opposed to 
single cellular in vitro analysis. Since animal testing and clinical trials are costly and have high 
failure rates (90-95% failure rate between animal testing and clinical trials35), many have 
attempted to identify biological targets before performing such tests. While there are many 
complex iterations of the route,  the two most common are direct binding to purified proteins or 
phenotypical evaluations with a variety of cell lines.36 For Taxol, it took an additional 9 years to 
determine its biological activity.28 For some natural product pharmaceutical agents, the 
biological targets are still unknown.27 In some cases, following the incorrectly assumed 
biological target has potentially posed significant cost, wasted unnecessary resources, and 
delayed discoveries of a treatment as is one theory for the 412 failed clinical trials over 10 years 
of Alzheimer drugs targeting amyloid-β protein instead of the now theorized root cause of 
bacterial/fungal infections.37,38 
 
1.3.2 The Debate of Rational Design Versus Natural Products 
In the 2000s, there was a major push towards synthetic libraries which would eliminate 
the delays associated with drug discovery as these compounds were already designed with 




not been as fruitful as originally hoped. At the same time, advancements in robotics and 
computational analysis programs have helped high throughput analysis of drug discovery. These 
tools have resulted in rapid assay screening, as well as advanced prefractionation, which can be 
as unique as each drug program sometimes separating a crude fraction into 5-15 samples41 or 
into about 200 fractions with an estimated 1-5 compounds each.42,43 The differences in 
prefraction are largely tailored to the resources available to the lab and the nature of the extracts, 
but the general benefit of prefractionation to such an extent allows for rapid dereplication, which 
prevents a major bottleneck in current drug discovery: scientific labor in isolation and compound 
elucidation. It also allows detection of highly active yet minute quantities of novel compounds. 
While some have questioned the usefulness of natural products, computational studies have 
shown that natural products occupy a more diverse (larger and more complementary) region of 
chemical space than other (synthetic) sources.27,44 This has been supported by the continued 
frequency of natural product and derivative drug approval rates which have been consistently 
occupying 39% of approved drugs from 1981-2010.44  
 
1.3.3 Prospects for the Future 
As natural product drug discovery progresses into the future, soil microorganisms and 
marine sources are prime sources for novel drug candidates. Between 1981-2006, there were 24 
new natural product entities that made it past phase II clinical studies, 16 of which were from soil 
microorganisms.27 One possible reason for this is that soil is “extraordinarily rich in unique 
species.”45 Since there is an estimated 2-5 million different fungal species, of which only 




advanced culturing techniques are developed, as this dissertation shows with the isolation of new 
analogues of asteltoxin with increased stability and activity within a spheroid assay.  
There is a new frontier that is further being explored by natural product drug discovery 
scientists: endophytes.48–52 Endophytes, organisms that coexist within a plant’s tissues without 
being pathogenic for at least part of their life cycle, can behave symbiotically as well.53–55 Often, 
this symbiosis manifests by producing compounds that are antimicrobial to eliminate other 
pathogens that threaten their host environment.51  They have also been theorized to produce 
nutrients for the host plants as well as modify the plant’s own antimicrobial compounds to either 
increase toxicity or specificity towards organisms other than themselves.53–55 Not only are these 
endophytes a new frontier as a source for novel organisms and novel compounds, endophytes 
have begun to be utilized in other aspects of drug development. For instance, recent fermentation 
practices have used endophytes produce the precursors for paclitaxel to be able to meet the 
clinical demand without harvesting the host plants to extinction.29–34 For complex natural 
products that are difficult to obtain through total synthesis, these fermentation practices are also a 
new frontier of natural product technologies. 
One area these fermentation-only practices lack is with the incorporation of certain 
atoms, like fluorine, which has unique electronic properties. When placed in the correct location, 
the small size yet high electronegativity and potential to accept hydrogen bonds of fluorine can 
cause compounds to increase their half-life by resisting proteolysis as well as changing binding 
affinities. As new compounds are identified from unique sources such as endophytes, another 
frontier is to logically substitute these fluorine atoms into key locations using synthetic 
chemistry. These syntheses have been more attainable following the organometallic synthetic 




formation of carbon-carbon bonds. More recently, organometallic synthesis have begun finding 
regioselective routes for the formation of carbon-fluorine bonds.56 These practices of 
incorporating fluorine into known APIs (active pharmaceutical ingredients) have already begun 
making an impact on the market. In fact, in 2015, approximately one in five drugs (including 
immunoglobulin drugs) contained fluorine and its incorporation has increased to nearly one-third 
of the newly approved small-molecule drugs.57 
With the new atom comes a new benefit to drug discovery. Fluorine’s only isotope, 19F, is 
NMR active. While this dissertation covers the rapid quantification of 19F with an external 
standard, and this is applicable in the synthetic/medicinal chemistry area of drug discovery, this 
technique may eventually be applied to one of the most difficult transitions of specialties in drug 
discovery, the in vitro to in vivo. It has long been argued58 that animal studies are not adequate 
predictors of efficacy in humans, and genetically modified mice for a phenotypic response might 
not have the same irregularity as the human disease state. For that reason, low-dose clinical trials 
have become more commonly accepted for drug submissions before full in vivo testing.58,59 
These low-dose preclinical trials are directly benefitted by the 19F NMR development presented 
here as more and more drugs become fluorinated. Eventually, pharmokinetics and bioavailability 
will be able to be quantified directly in biological media with fluorinated compounds without the 
need of animal testing and potentially decreasing the failure rate in clinical trials with adequate 
analysis during pre-clinical trials.  
Other potential advances to decrease the failure rate between in vitro and in vivo testing 
can include advanced assays such as the spheroid assay (discussed within chapter 4) or the 
organ-on-a-chip, small chips containing specialized human cells in an environment that better 




gap between the fields are lacking in the field. For instance, a paper by Amgen analyzed 53 
“landmark” studies and found that only 11% were reproducible.62 Its concluded that since the 
majority of these failures occurred between switching of project experts (eg. drug discovery to 
medicinal chemists to clinical), it is important that the communication between the lines of 
clinical, medicinal chemists, and drug discovery chemists improve their communication, and 
proper preclinical validations of primary scientific data before engaging in clinical trials is 
necessary.62 
 
1.3.4 Summary and Relevance to Dissertation 
In summary, natural products have been the source of medicine throughout the ages, 
being found with remains over 5300 year ago,10 in written records of applications over 2900 
years ago,18 and influencing cultures which have in turn created symbols that have persevered 
through modern days.12 Applications of natural products have only become more successful with 
the advent of new technologies that can be isolated for the specific active compounds as seen 
with penicillin, be modified for quantity as is seen with the semi-synthesis and now fermentation 
of paclitaxel, and be predicted as is seen with in silico modeling and exploring chemical space. 
This work helps advance the field for the future of natural products by developing 
quantitative 19F NMR to help in the development of the analysis in fluorinating natural products. 
The fluorination of natural products is a trend already seen in FDA approvals due to 19F unique 
characteristics such as being relatively small for a hydrogen bond acceptor and its 
electronegativity which has been shown to be able to increase inherent stability of compound 
when substituted at specific locations as well as help molecules resist enzymatic degradation. 




monitor these compounds in environments that would originally be difficult to analyze (via 19F 
NMR). Further development on this would might allow direct analysis in media, such as blood, 
that would be unsuitable to analyze unprocessed samples such as HPLC or MS. 
Additionally, seen in this work are isolations of a polyketide with anticancer properties 
and a cyclic peptide with antifungal properties. Both compounds come from fungi, a source 
underexplored with only an estimated 2% of species isolated. These fungi were isolated from a 
soil sample and a leaf respectively. The organism from the leaf, Spaceloma corylii, was behaving 
as an endophyte which are relatively unexplored for chemical constituents due to their difficult 
isolation in high-throughput methods. Both chapters also investigate non-traditional assays 






Chapter 2: Hypothesis and Chapter Overviews 
2.1 Introduction 
This chapter introduces the prevalent hypothesis mentioned in the following section, as 
well as the hypothesis for each of the following chapters distinguished in individual sections. 
After the hypothesis, an overview is presented summarizing the content of the chapter. 
 
2.2 Research Questions 
The natural product pipelines to drug discovery have experienced many upgrades to 
increase productivity; however, new innovations are still needed to overcome backlogs that arise 
in identifying appropriate lead compounds. These backlogs can occur from culturing new 
sources of organisms, creating appropriate assays to limit failed in vivo or clinical trials, or 
quantifying bioavailability during pre-clinical trials. Advancements in the tools used within 
natural product pipelines can lead to new potentially active pharmaceutical ingredients. Due to 
the diverse background of fungi and that only an estimated 2-10% of potential fungi have even 
been characterized, fungi represent an ideal source for new natural products. Can advancement 
in the proper tools be used to identify better lead compounds prior to clinical trials? 
 
The primary research question was tested using the following specific research questions: 
1. Can an external standard be used to rapidly yet accurately quantitate active 
pharmaceutical ingredients (APIs) containing fluorine via a 19F NMR method? 





3. Can a high-throughput laser cutting device isolate an endophyte with a previously 
unidentified natural products?  
 
2.2 Chapter 3.  Applications of 19F Quantitative NMR to Pharmaceutical Analysis 
 Incorporation of fluorine into active pharmaceutical ingredients can be beneficial to 
important properties such as metabolism, stability, and selectivity. This has resulted in nearly 
one-third of the newly approved small molecule drugs containing at least one fluorine atom. This 
100% naturally abundant isotope, 19F, can therefore be easily identified even in complex 
mixtures. Despite the potential, 19F quantitative NMR (qNMR) has been slow to develop. Herein 
is presented experimental methodologies utilizing optimized parameters for uniform 
quantification of fluorine containing drugs. Validation has been confirmed using both 
gravimetric and absolute concentration data reduction. The specific research question was found 
to be supported as an external standard can be used to accurately quantitate fluorinated 
compounds rapidly. This has a far-reaching impact as this technique may currently be 
implemented in medicinal and synthetic chemistry by quantitating synthesized compounds 
within non-deuterated solvents that would otherwise be unquantifiable in 1H NMR quantitation. 
After further minor optimization, this method may be used during pharmokinetic analyses to 
quantitate bioavailability within blood without modification to the sample. 
 
2.3 Chapter 4. Asteltoxin G Is a Selective Toxin of Pancreatic Cancer Line Spheroids While 
Preserving Normal Fibroblasts and Normal Pancreas Spheroids. 
 In this project, a fungal extract screening program was initiated on cells grown in 




pancreatic cancer cell lines while remaining safe to NIH/3T3 normal mouse fibroblasts and 
hTERT-HPNE normal pancreas ductal cells.  One extract out of 3,588, isolated from a soil 
sample from a forest near Mt. Hood, Oregon and later identified as Pochonia suchlasporia, 
distanced itself from all others in its selectivity for cancer cell lines. It was subjected to bioassay-
guided fractionation, which yielded a new asteltoxin derivative, named here as asteltoxin G, as 
well as 2 other polyenic alpha-pyrones: asteltoxin and AB5529. Two known compounds from 
other classes were also isolated, sclerotinin A, and (-)-terpestacin. To further examine the in vivo 
applicability of this set of compounds, a three-dimensional spheroid assay, was developed using 
the Perkin Elmer Operetta High Content Imaging System. Asteltoxin G caused a more than five-
fold reduction in MIA PaCa-2 tumor spheroid volume at doses as low as 6.25 µM, while 
NIH/3T3 fibroblast spheroids and hTERT-HPNE E6/E7 spheroids were unaffected at the highest 
concentration tested (50 µM).  A selectivity index of >15 was found for the MIA PaCa-2 
spheroids compared to spheroids made of normal cells. These results indicate that asteltoxin G 
may be a more attractive chemical lead with regard to its in vivo efficacy, as well as illustrates 
the power of 3-D spheroid assays in drug development. 
 
2.4 Chapter 5. Isolation of Cyclic Peptide 
In this project, endophytes, organisms living within plants without being pathogenic, 
were isolated from a variety of sources via a new laser cutting apparatus. During the fungal 
isolation procedure, an inhibition zone was noted between two neighboring fungal colonies. The 
organism responsible for creating the inhibition zone was purified and shown to have an 
exceptionally slow growth rate. Three new cyclic peptides, herein termed persephacins A-C were 




fractionation. The resulting pure compounds were tested for activity against a variety of 
agricultural pathogens in vitro and in vivo, and the cyclic peptides were found to be the source of 
the antifungal activity. Additional studies assessed the potential application of the most active 
compound, persephacin A, as an agricultural antifungal compound. The bioassay data suggested 
there is a potential for developing this compound as an agricultural antifungal; however, its lack 
of mobility within plants may limit its applications. 
 
2.5 Other Noteworthy Contributions 
While this dissertation is highlighting three projects accomplished during my graduate 
career, there have been other noteworthy contributions on projects that have been accomplished 
in collaboration with other scientist and have led to publications/paper submissions. These will 
be addressed chronologically.  
Early work included my effort to culture fungi on increasingly deuterium rich media to 
isolate natural products with incorporated deuterium and LCMS analysis of metabolite profiles. 
Isolation, elucidation and paper composing was accomplished by Bin Wang and assays were 
completed by Jarrod King. The results were published in the Journal of Natural Products.63 
A second study involved compounds as potential countermeasures against liver toxicity 
from Alfatoxin B1, a potent carcinogen from the Aspergillus genus.64,65 Adam Carter isolated 
three compounds from Alternaria alternaria, and I identified two active compounds from 
Aspergillus niger. Semi-synthesis and structure activity relationships were explored by Adam 
Carter. Jarrod King developed and executed the assays. Paper submission pending Journal of 





Chapter 3: Improving Development of Natural Products with 19F NMR 
3.1: Abstract 
Incorporation of fluorine into active pharmaceutical ingredients (APIs) can be beneficial 
to improve its properties such as metabolism, stability, and selectivity. This has resulted in nearly 
one-third of the newly approved small molecule drugs containing at least one fluorine atom. The 
100% naturally abundant isotope, 19F, can therefore be readily detected in complex mixtures by 
NMR. Despite the potential for applying this method, 19F quantitative NMR (qNMR) has been 
slow to develop. Herein presents experimental methodologies utilizing optimized parameters for 
uniform quantification of fluorine in drugs. Validation has been confirmed using both 
gravimetric and absolute concentration data reduction. This chapter was published with minor 
formatting changes in Concepts in Magnetic Resonance Part A.66 
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3.3 Introduction 
Quantitative NMR (qNMR) is a well-established technique that has been adopted for a 
variety of uses.67–69 QNMR studies often rely on the use of hydrogen (1H) atoms due to their 
relatively high NMR sensitivity and ubiquitous presence in organic compounds. However, there 




is compressed into a relatively narrow band of 10 – 12 parts per million (ppm). Given the 
structural complexity of most analytes and analyte mixtures, signal overlap can be a significant 
problem. Second, accurately determining analyte concentrations by qNMR is challenging and 
prone to inaccuracies when samples consist of component mixtures that span wide dynamic 
range (e.g. pharmaceutical formulations that contain high concentrations of excipients relative to 
the active pharmaceutical ingredient). 
In comparison, 19F NMR has several advantages that make it well suited for use in 
qNMR. The sensitivity of the 19F isotope in NMR is comparable to 1H since it has a natural 
abundance of 100%, its Larmor frequency is nearly that of hydrogen, and it has a nuclear spin of 
½. Fluorine is also highly responsive to changes in its electronic environment; which equates to 
significant spectral dispersion and a functional chemical shift range of >200 ppm (Figure 3).70 
Moreover, the limited appearance of 19F in most natural and many synthetic compounds means 
that in most samples, the spectral region for 19F will be free from interfering resonances. This 
attribute imparts excellent selectivity for the technique, making it suitable for low level 
quantification of fluorinated isomers that are challenging to separate and quantify by traditional 
separation techniques including HPLC or GC. Finally, a 19F qNMR purity assessment can be 
performed on sub-milligram amounts of material in less than an hour including sample 





Figure 3. Overlaid 1H NMR Spectra  
(A, top) and overlaid 19F NMR spectra (B, bottom) of flumethasone pivalate (blue), fluconazole 
(green) and GDC-0339 (red) 
 
Assessment of an API, an active pharmaceutical ingredient, purity is critical throughout 
the drug development process. Traditionally, a battery of analyses utilizing GC and LC methods 
are utilized to detect organic impurities in the sample. Water content must usually be confirmed 




measured using an ICP technique. The time and material required for this purity characterization 
can reach upwards of weeks and hundreds of milligrams.  
Given these considerations, the use of 19F for qNMR in pharmaceutical analysis settings 
is quite promising. This is based in part on the fact that in 2015, approximately one in five drugs 
(including immunoglobulin drugs) contained fluorine and its incorporation has increased to 
nearly one-third of the newly approved small-molecule drugs.57 There are multiple reasons for 
the growing use of fluorine in drug substances, many of which are based on fluorine’s ability to 
alter the physical and electronic properties of an API.  
Despite its potential utility, comparatively few qNMR studies have been reported that 
utilize 19F nuclei for analyses in the pharmaceutical industry. Among the reports which have 
appeared, research has been focused on using 19F for polymorph analysis,71 reaction 
monitoring,72 and mass balance measurements.73 However, the requirements for accurate qNMR 
measurements necessistate the evaluation of additional experimental constraints including 
excitation bandwidth and digital resolution, which to date have not received in-depth 
experimental evaluations. 
 Presented herein is the analysis of several critical features of 19F NMR that must be 
controlled to collect quantitative NMR data. Data were presented comparing results obtained 
using two methodologies: traditional internal reference approach and single point calibration 
with absolute intensity method.74,75 Additionally, several important data processing parameters 





3.4 Results and Discussion 
3.4.1 Acquiring Quantitative 19F NMR Spectra - T1 Relaxation  
 One of the first parameters to optimize is the T1 relaxation. The spin-lattice relaxation 
time, or T1, is a measurement of the rate constant for the magnetic vector to return to 
equilibrium. As with all quantitative NMR experiments, T1 relaxation must be considered. There 
are several approaches that can be used to ensure that differences in the relative relaxation rates 
of resonances in the analyte do not negatively impact quantitative analyses. 
The simplest method is to remove the impact of relaxation by measuring a single 
transient for each data set. A limiting factor for this approach is the recoverable signal-to-noise 
for the data set. Given that relaxation is not a factor using this approach, a 90 degree tip angle 
can be safely used to maximize the signal available in a single transient. 
The most commonly employed technique to provide reliable signal amplitudes is to wait 
for a period at least 5 longer between acquisitions (acquisition time plus the interpulse delay) 
and the T1 of the slowest relaxing signal of interest. This provides approximately 99.33% 
relaxation. To decrease relaxation error, waiting approximately 8  T1 results in approximately 
99.97% relaxation. 
For the purpose of demonstrating the effects of T1 relaxation, an inversion recovery T1 
analysis was performed on fluconazole, flumethasone pivalate, and GDC-0339. The longest T1s 
were observed in fluconazole and flumethasone pivalate at approximately 1.1 seconds. 
Therefore, the relaxation delay was set to 8.25 s and the acquisition time to 1.75 s, yielding a 
total of 10 s, or 9  T1 for all measurements.  
Pulsing the sample during receiver gain adjustment then acquiring data without full 




overcome this problem, it is recommended that the gain is set to a value that is low enough to 
prevent saturation of the signal and/or waiting a sufficient period of time before starting the 
experiment to ensure nuclei are fully relaxed. 
 
3.4.2 Acquiring Quantitative 19F NMR Spectra - Tip Angle 
 When a single transient is used to record a qNMR spectrum, the pulse width required for 
a 90 degree rotation of the magnetization is the best choice to maximize signal to noise (S:N). 
However, if signal averaging is required to build up acceptable S:N, then the most efficient 
combination of tip angle and relaxation delay can be calculated based on a predetermined 
acceptable level of error.76 For most applications, the optimal values, with respect to signal per 
unit time, will be just less than the widely accepted 90 degree tip angle and 5  T1. The selection 
of a tip angle is not critical; however, smaller tip angles will allow shorter total relaxation times. 
 
3.4.3 Acquiring Quantitative 19F NMR Spectra - Acquisition Time  
 The acquisition time, defined as the time interval during which the receiver is recording 
data, should be set to the reciprocal of the half-height line width for the signal of interest. For 
most routine small molecule quantitative 19F applications, line widths will be on the order of 0.5 
Hz. Therefore, acquisition times of 2 – 2.5 s are appropriate. Increasing the acquisition time 




 Figure 4. Simulated Excitation Profiles 
Simulated excitation profiles of a 90° tip angle (9.6 µs pulse, top, blue) and a 30° tip angle (3.2 
µs pulse, bottom, red) The maximum spectral sweep width resulting in uniform signal excitation 
for a 90° tip angle is 36.7 kHz (130 ppm for 19F at 300 MHz) while a 30° tip results in 56.4 kHz 
(200 ppm for 19F at 300 MHz) 
 
3.4.4 Acquiring Quantitative 19F NMR Spectra - Excitation Bandwidth 
 The excitation profile of a nominal 90-degree square pulse is shown in Figure 4 on top in 
blue. The width of the excitation window is proportional to the intensity of the radiofrequency 
field B1 during that pulse (or inversely proportional to a nominal 90-degree pulse width). For 
quantitative applications, all resonances in the spectrum must be excited uniformly; therefore a 
broad excitation profile is required for accurate results. In the case of 1H NMR, pulse widths are 




This is more than adequate for uniform 1H signal excitation. However, for 19F NMR the spectral 
window can be in excess of 200 ppm or ~100 kHz on an 11.7 T spectrometer (i.e., a proton 
frequency of 500 MHz). The power handling limitations of an NMR probe typically do not allow 
a uniform excitation of such large bandwidths using a square pulse.  
Four methods can be employed to overcome this limitation. First, when the peaks of 
interest are located in close proximity to one another, the transmitter can simply be set close to 
the peaks of interest. Second, multiple spectra can be collected where the transmitter is located 
near the peaks of interest; however, this results in increased total experimental time due to 
multiple acquisitions, increased data storage and manipulation, as well as potential instrument 
and data interpretation errors. Third, a shorter excitation pulse at the same power level can be 
used resulting in a broader excitation window, albeit with a sacrifice in S:N per transient (seen in 
Figure 4). Fourth, a shaped radio frequency pulse can be employed to increase the excitation 
bandwidth without increasing the power handling demands on the hardware. This approach was 
elegantly demonstrated by Power, et. al.77 wherein the use of a shaped pulse sequence dubbed 
CHORUS (CHirped, ORdered pulses for Ultra-broadband Spectroscopy) provided nearly perfect 
excitation over a very large bandwidth through the use of multiple CHIRP pulses.78 The use of a 
CHORUS pulse for excitation is limited to cases where there is not a strong JFF coupling due to 
perturbations in lineshape under this condition. 
 
3.4.5 Acquiring Quantitative 19F NMR Spectra - Signal to Noise 
 It is clear that the uncertainty in measuring the amplitude of a signal increases as the S:N 
of the data decreases. A report of the parameters critical for qNMR validation has confirmed this, 




<1% uncertainty in the measurement.79 The effect of S:N on accuracy was also observed during 
this absolute intensity method development, as seen below in Figure 5.  
 
 
Figure 5. Correlation of S:N and Experimental Error. 
19F (1H coupled) spectra of a fluconazole signal showing direct correlation between increasing 
concentration, increasing S:N and decreased experimental error: A: top (red) is a sample at 0.5 
mmol/L (0.1 mg/mL), S:N 7, Error: N/A, B: middle (green) is a sample at 4 mmol/L (1 mg/mL), 
S:N 46, Error: 10%, and C: bottom (blue) is a sample at 10 mmol/L (2mg/mL), S:N 112, Error: 
3%. Errors were calculated relative to gravimetrically determined concentrations.   
 
3.4.6 Acquiring Quantitative 19F NMR Spectra - Number of Transients 
 There is no direct impact on the quality of a qNMR result that can be related to the 




be considered. Relaxation errors are often a significant part of the uncertainty in a qNMR 
measurement. By collecting data with a single transient, errors induced by relaxation are 
avoided. In contrast, summing multiple transients increases the S:N of the aggregated data as a 
function of 2n with respect to the number of transients collected, and it averages scan-to-scan 
variations due to environmental issues such as vibration.  
 
3.4.7 Processing Quantitative 19F NMR Spectra - Apodization 
 Apodization refers to the practice of applying a weighting function to the time-domain 
data before the Fourier transformation is applied. Apodization can be used to enhance the data in 
numerous ways, but for qNMR methods the primary objective is to reduce the noise in the data 
and smooth the resulting spectrum. This results in increasing the effective S:N ratio. The average 
line width for most small molecules will be 0.4 – 0.6 Hz at half-height. Therefore, application of 
an exponential weighing function of about 0.5 Hz is useful to suppress noise without 
significantly broadening the lines of interest. 
 
3.4.8 Processing Quantitative 19F NMR Spectra - Fourier Number 
 More digital data points in a FID result in better digital resolution of the spectrum. 
Accordingly, one might be tempted set the number of points collected to a very large number. 
This approach is too simplistic and when taken to an extreme, it degrades the quality of the 
resulting data. There is a linear relationship between the number of points collected in the FID 
and the acquisition time. As noted above, the acquisition time is best set to match the reciprocal 




leads to a decrease in S:N (i.e., collecting only noise after the signal has decayed). As seen in 
Figure 6, digital resolution critically impacts the error in the measurement. 
 
 
Figure 6. Digital Resolution Comparisons 
Digital resolution comparisons between 512k (top, blue), 128k (middle, green) and 32k data sets 
of 1H and 19F spectra. The wide sweep width of 19F relative to 1H yields fewer data points and 
increased error in quantitation which can be compensated for through zero filling. 
 
 For the case of 1H NMR spectra, the spectral window is limited and the resolution 
afforded by setting the number of points based on the half-height relationship is reasonable at 
average field strengths (e.g., 14T). However the spectral bandwidth for 19F is much larger. To 
overcome the problems associated with unacceptably long acquisition times, a technique known 




acceptable total number of data points are reached. The total number of points is known as the 
Fourier number, which is the number of points used in the Fourier transform. The result is 
essentially the same as collecting more data points without an increase in noise due to addition of 
zeros to the decayed potion of the FID. Other than increased computational effort, there is no 
detriment to increasing the Fourier number. 
 
3.4.9 Processing Quantitative 19F NMR Spectra - Data Reduction 
Measuring the highest quality data requires care and attention to experimental 
parameters, but the boundaries for these tasks are generally well defined by physics and 
mathematics.80 Once data are collected and transformed into a spectrum, the next step is data 
reduction to generate interpretable results. Some parts of data reduction are well defined by 
theory while others are more subjective. One published study involving 33 different facilities 
found 4% uncertainty between qNMR results despite following a strict protocol.14 A portion of 
this variability could be attributed to manual phasing and baseline correction, which are often 
influenced by human factors. 
 
3.4.10 Processing Quantitative 19F NMR Spectra - Extracting Peak Intensities 
Measuring peak intensity can be done using several methods. The traditional approach is 
to choose appropriate break points for an integral region and calculating the area under the curve 
between them. Setting the correct location of the integral break points should be done based on 
line width. For example, assuming a pseudo-Lorentzian lineshape, the integral should extend for 
a distance equal to +/- 32 the half height to include 99% of the signal intensity.81 To achieve an 




height. Typically, an acceptable signal from a small molecule is ~0.5 Hz wide which yields an 
area integral of 86.4 Hz. This limitation should be easier to satisfy for 19F than 1H, but there will 
be cases where integration without interference from other resonances will be problematic. For 
these reasons, a quantitative deconvolution method can be employed to good effect when 
spectral crowding precludes peak area integration.  
Signal deconvolution is accomplished by using mathematical methods to fit each line in 
the data set to the models that represents the single resonance peak.82 The models are accurately 
calculated and the sum of integrals provide an amplitude for the resonances under investigation. 
This method avoids the uncertainties in integration that arise from overlap and baseline errors, 
but suffers from reliance on near-perfect lineshape for the highest quality results. Schoenberger 
and co-workers83 have demonstrated that a combination of integration with Global Signal 
Deconvolution84 can be used to accurately extract the true amplitude of a desired peak by 
integrating the area containing the signal of interest, then correcting the size of that integral value 
by subtracting the deconvoluted intensities of interfering signals.  
 
3.4.11 Conversion of Signal Intensity to Concentration - Internal Standard Versus Absolute 
Intensity  
 The linearity and reproducibility of modern NMR systems can be leveraged to provide 
quantitative NMR results that do not require the addition of an internal standard.85 Modern 
spectrometers are stable, linear, and highly reproducible, allowing a single point calibration to be 
used as a reference for subsequent data (S=kN: S is signal, N is number of nuclides, and k is a 
proportionality constant86). While this can be manually calculated, it can be time consuming and 




 The software provided with both Agilent and Bruker spectrometers have the built-in 
capability to perform quantitative calculations. The Agilent method is predicated on a calibration 
stored in the probe file, while the Bruker method requires a second data set collected on a 
standard sample.   
A commercially available software tool in Mnova NMR data processing package from 
Mestrelab uses a method analogous to that in the Agilent system. It will automatically compute 
the quantitative results relative to a calibration file (Mnova termed calfile) to provide users a 
simple-to-implement 19F qNMR method for routine pharmaceutical analyses. 
 To perform experiments in the absence of an internal standard using the Mnova tool, a 
sample of known purity and concentration is first measured to calibrate the response of the 
system to the standard sample (Mnova termed concentration conversion factor, CCF). The CCF 
is saved along with the data acquisition parameters used to collect the calibration spectrum in the 
calfile. Once this calibration factor is available, it can be used to scale the integrals of any 
subsequent data set to yield sample concentration. The software can accommodate for 
differences in the number of transients, the value of the receiver gain, and the tip angle used to 
collect the reference spectrum and the analyte spectrum since these parameters all affect the 
intensity of the spectrum in a predictable, mathematical way.80  
 
3.3.12 Implementation of Absolute 19F qNMR Method 
 For the current study, all NMR data were collected on a 300 MHz broadband NMR 
spectrometer unless otherwise noted. A 30 degree tip angle (3.2 µs excitation pulse) was used to 
yield over 60 KHz (200 ppm) of excitation bandwidth. A total delay of 10 s (~ 9 x T1) was used: 




hundred and twenty eight transients were recorded and the resulting data were processed using 
0.3 Hz exponential apodization and zero filled from 128k to 512k data points. Total time for each 
experiment was less than 25 minutes. 
Samples of fluconazole, flumethasone pivalate, and GDC-0339 were prepared in DMSO 
across a concentration range of 0.9834 mM to 91.96 mM, 0.8141 mM to 76.12 mM, and 0.1815 
mM to 23.99 mM, respectively. The 9.188 mM fluconazole sample was used as the calibration 
standard for the absolute intensity method. Of the two fluconazole fluorine signals, the signal at  
-111.4 ppm was used to generate the Mnova calfile. 
The calfile was created by acquiring a quality spectrum of the 9.188 mM fluconazole 
sample. Next, the signal at 111.4 ppm was analyzed with the multiplet global signal 
deconvolution tool. In the quantitation tab of the Mnova ribbon, the concentration window was 
opened and the concentration, signal, and number of nuclides updated in the settings. The 
calculated CCF settings were saved as the fluconazole calfile.  
The calfile was referenced to compute the remaining fluconazole sample concentrations 
(n = 7) and compared to the gravimetrically calculated concentrations to confirm linearity. The 
resultant R2 value was 0.9999. Robustness was determined by referencing this fluconazole calfile 
to determine the concentration of flumethasone pivalate (n = 8) and GDC-0339 (n = 6). The 
resultant R2 values were 0.9969 and 0.9996, respectively (see Figure 7). The average percent 






Figure 7. Method Linearity 
Linearity was confirmed when comparing absolute intensity extrapolated at qNMR concentration 
from MNova software (Calfile, y axis) versus gravimetric concentrations (x axis). A. 
Flumethasone pivalated exhibited an R2 value of 1.0000, a slope of 0.972 ± 0.002 and an average 
percent error of 2.9% (range ~0.81-76.1 mmol/L), B, Fluconazole exhibited an R2 value of 
0.9999, a slope of 1.001 ± 0.004, and an average percent error of 3.5% (range ~0.98-92.0 
mmol/L), and C, GDC-0339 exhibited an R2 value of 0.9996, a slope of 1.03 ± 0.01, and an 
average percent error of 3.8% (range ~0.18-24.0 mmol/L) 
  
The same fluconazole and flumethasone pivalate samples were run in repetition to 
determine the standard percent deviation introduced by the instrument itself. It was found to be 
2.8% and 2.6% for fluconazole and flumethasone pivalate, respectively, suggesting a significant 
contribution of the error occurred from the spectrometer and environment rather than the method. 
Another test of robustness important to this method is how well it transfers to other 
instruments. Using the experimental parameters described above, data were acquired on varied 
fluconazole (n = 5, 0.4917 – 45.42 mM) and flumethasone pivalate (n = 5, 0.4071 – 37.59 mM) 
samples using a 400 (376.49 MHz) MHz broadband NMR. A new Mnova calfile was generated 
relative to the 9.188 mM fluconazole spectrum. The average error associated with the 
fluconazole concentrations was reduced to 2.8% and the flumethasone pivalate concentration 
error was reduced to 2.3%. Duplicate sample analyses revealed a similar average error to the 




 The mean average errors were determined relative to traditional internal standard 
measurements and assumed no error in their weight measurements. Overall, all mean average 
errors using the absolute intensity method were less than 4%, which included S:N levels as low 
as 50:1. These results suggested that the experimental methods and analysis tools (i.e., Mnova 
qNMR software) provide acceptable results for 19F qNMR analysis. 
 
3.4 Conclusions 
 There are advantages to both the traditional and the absolute intensity qNMR methods. 
Using the traditional approach requires that a suitable reference standard of known purity and 
appropriate stability is available. The reference standard must be soluble in the same solvent as 
the analyte, it must be non-reactive in the test sample, it must provide suitable resonances for 
analysis that are non-interfering with the spectrum of the analyte, and it must be readily available 
and affordable. Obviously, it can be difficult to find such compounds for all situations. 
Experimentally, the traditional approach requires that two samples, the analyte and the reference 
material, each be weighed with appropriate accuracy. Given the constraints on sample size and 
volume for NMR analysis, it is not unexpected that weighing errors represent the most 
significant source of uncertainty for qNMR results. 
While the absolute intensity method essentially circumvents these limitations, it too 
suffers from shortcomings. This technique is predicated on the idea that the volume of sample 
interrogated by the NMR coil is constant for both the calibration and the experimental 
measurement. In practice, an NMR coil observes signals from the region outside the physical 
dimensions of the coil itself and care must be taken to assure that the calibration sample and the 




used between the two samples should be the same to limit error in the measurement. The console 
of an NMR system is not in a temperature controlled cabinet and anecdotal evidence suggests 
that the temperature of the electronic components, particularly those components that mix or 
filter frequencies, affects their performance. As such, the calibration analysis should be made at 
the same room temperature as the experimental analysis. This condition is easily achieved by 
using a run-time calibration at the cost of extra work and spectrometer time for every study. 
Finally, the Q of the NMR coil must be the same when collecting data for the calibration 
standard and the analyte. Therefore, each sample must be tuned equally well. The sample-to-
sample variation in the Q of the coil will be strongly dependent on the probe architecture, with 
greatest susceptibility to dielectric changes occurring when acquisition is performed on the inner 
coil of an Alderman-Grant style probe. 
In conclusion, a general guide for the application of 19F qNMR measurements to 
pharmaceutical samples has been presented. Implementation of the absolute intensity qNMR 
methodology enables organic and analytical chemists to collect their own qNMR measurements 
to evaluate the purity of fluorine-containing compounds without the addition of time and labor 






Chapter 4: Isolation of Asteltoxin Derivative 
4.1 Abstract 
 In this project, a fungal extract screening program was initiated on cells grown in 
monolayer looking for compounds with selective toxicity that killed MIA PaCa-2 and Panc-1 
pancreatic cancer cell lines while remaining safe to NIH/3T3 normal mouse fibroblasts and 
hTERT-HPNE normal pancreas ductal cells.  One extract out of 3,588 showed the desired 
characteristics. That extract had been prepared from a fungus isolated from a soil sample 
collected from a forest near Mt. Hood, Oregon and later identified as Pochonia suchlasporia. 
The fungal extract was subjected to bioassay-guided fractionation, which yielded a new 
asteltoxin derivative, named here as asteltoxin G, as well as two other polyenic alpha-pyrones: 
asteltoxin and AB5529. Two known compounds from other classes were also isolated, 
sclerotinin A, and (-)-terpestacin. To further examine the in vivo applicability of this set of 
compounds a three-dimensional spheroid assay was developed using the Perkin Elmer Operetta 
High Content Imaging System.  Asteltoxin G caused a more than five-fold reduction in MIA 
PaCa-2 tumor spheroid volume in doses as low as 6.25 µM, while NIH/3T3 fibroblast spheroids 
and hTERT-HPNE E6/E7 spheroids were unaffected at the highest concentration tested of 50 
µM.  A selectivity index of >15 was found for the MIA PaCa-2 spheroids compared to the 
normal cell line spheroids.  
 
4.2 Acknowledgements 
The organism was originally isolated by the “chemical zoo” team, specifically Sara Helff, 
and Carolyn Le. Jarrod King researched, initiated and performed assays. NMR was completed on 




chemical analyses were performed by Allison Mattes. Data were analyzed and reported by 
Allison Mattes, Jarrod King, and Robert Cichewicz. 
 
4.3 Introduction 
Pancreatic cancer is projected to become a leading cause of cancer-related death by 
2030.87 It has a poor survival rate of only 7.7% after 5 years,88 and has had little progress in 
treatment since gemcitabine became the lead treatment in 1997.89 Most advances since its 
discovery have been combination therapies with gemcitabine, but with only modest success (i.e., 
prolonging life by an average of only 4 months).89 The difficulty in treating pancreatic cancer 
arises from many factors such as late detection of the disease, tumor heterogeneity, early 
recurrence, and high incidence of resistance even when the cancer is caught early.90  
 There is a dire need to explore new chemical space to find compounds to address the 
need for new therapies, but the identification of a potential pancreatic cancer drug relies heavily 
on the use of limited assay systems. One of the first limits of assays are the source of the cells. 
There are two types of cells that can be used: primary (directly taken from the parent source with 
a finite lifespan) or immortalized cell lines (genetically manipulated primary cells). While 
primary cells may more closely mimic the disease state as they are not genetically mutated, they 
are problematic as they are slow growing with a finite lifespan.61 Additionally, samples may 
have high genetic variability, even of the same class of disease, causing reproducibility issues.61 
Alternatively, immortalized cell lines have genetic alterations that can cause changes in hormone 
signaling pathways that may not be easily identifiable due to the complexity of cells and current 
biochemical knowledge, and they may further experience genetic drift upon repeated culturing 




problem with cell lines, both in the cases where a fast-growing contaminate cell, like the HeLa 
cells, can overtake a culture in a few generations, or in the case of mycoplasms, that are found in 
up to 15-35% of cell lines.61 We decided to use well known cell lines due to the reproducibility 
and large quantity needed for high-throughput screening, as primary cell lines would be too 
impractical. Contamination issues were negated by periodically testing the cell lines for genetic 
purity.91  
While cancer is an extremely heterogeneous classification, most cancer cells do share 
common hallmarks, such as resistances to cell death, dysregulation of cellular energetics, 
sustained proliferative signaling, evasion of growth suppressors, avoidance of immune 
destruction, enabled replicative immortality, tumor-promoting inflammation, activation of 
invasion and metastasis, inducing angiogenesis, and genome instability and mutation,92 which 
indicates that theoretically druggable targets do exist. This technique of targeting hallmarks of all 
cancers is utilized by many of the current anticancer pharmaceutical agents. Since a shared 
attribute among cancers is the high rate of replication, (e.g., the result of sustaining proliferative 
signaling) certain anticancer compounds that arrest essential steps in mitosis, such as the tubulin 
binding ability of paclitaxel, have been successful.93 We hypothesized that compounds could be 
identified to specifically target the common mutations found in pancreatic cancer, while sparing 
normal cells.94  
Another criticism of traditional monolayer assays has historically been that they do not 
properly mimic the 3-D environment of a tumor. This is important because cells display complex 
signaling pathways that are often dependent on receptors interacting with adjacent cells.92 In fact, 
one of the hallmarks of cancer cells, is that they often reduce the signaling of these receptors 




challenge to the penetration ability of a compound because it tests a compounds ability not just to 
penetrate one layer of cells, but it also requires penetration between multiple cells and/or through 
the lipophilic environment between two adjacent cells.95 To counter this, cytotoxicity testing 
using 3-D cancer spheroids was developed. Spheroids have been shown to more closely replicate 
the in vivo effects of drugs due to increased cell-cell interactions and signaling, increased 
hypoxia in the interior of the spheroid, as well as the physical size and multiple layers of cells 
that must be penetrated by a drug.96 Spheroid assays can be applied either to crude extracts or 
pure compounds as an important step between in vitro and in vivo assays. As part of our research 




Figure 8. Compounds Isolated from Pochonia suchlasporia 






4.4 Results and Discussion: 
4.4.1 Screenings 
Extracts were initially tested on MIA PaCa-2 pancreatic ductal adenocarcinoma and 
NIH/3T3 normal mouse fibroblast cells in monolayer assay. To further examine the specificity of 
our hit, extracts were further tested against Panc-1 pancreatic ductal adenocarcinoma and 
hTERT-HPNE normal pancreatic duct cells immortalized with telomerase.  MIA PaCa-2 and 
Panc-1 are well-studied pancreatic tumor lines that bear many of the mutations that are typically 
found to be altered in pancreatic tumors in vivo such as KRAS, TP53, and CDKN2A/p16 (100%, 
50%, and 98% of tumors, respectively).97  The cell lines also possess robust growth rates, low 
adherence to extracellular matrices (resulting in higher instances of metastasis), and higher 
quantities of pro-angiogenisis (artery/vein forming) factors.97  For counter-screening, the 
NIH/3T3 mouse fibroblast line was chosen due to its normal cellular phenotype and non-
tumorigenicity.7  In addition, and in contrast to human cells, mouse cells will spontaneously 
immortalize with ease in culture due to the presence of inherent telomerase activity.98 We 
hypothesized that this natural tendency to immortalize in cell culture would yield cells with low 
background mutation rates.99,100 The hTERT-HPNE line was chosen as the second normal line 
due to its human origin, lack of tumorigenicity, and its close similarity to normal pancreatic 
ductal cells, as reported in the literature.101 Unlike the tumor-forming lines chosen, the hTERT-
HPNE line expresses normal KRAS, TP53, and CDKN2A/p16 gene products. Another positive 
attribute of using the cell lines that were chosen was that all four lines could be grown in RPMI 
medium (supplemented with EGF in the case of hTERT-HPNE), removing media differences as 




 Based on its inhibiting activity in monolayer selectivity assays, a promising fungal 
extract was selected and the fungus regrown. Based on ITS sequence data, the fungus was found 
to be Pochonia suchlasporia. While there have been anticancer compounds (pochonins)102 
reported from this fungus, these compounds were not observable via LCMS dereplication. 
Therefore, the extract was deemed suitable for compound identification and assays. 
 
4.4.2 Compound Identification and Structure Elucidation 
The Pochonia suchlosporia was grown Cheerios,TM and after 4 weeks, the fungus was 
homogenized and extracted with ethyl acetate to yield 89 g of crude extract. A stepwise gradient 
consisting of hexanes, dichloromethane, and methanol on a silica column afforded 40 g of an 
active fraction from the 9:1 dichloromethane:methanol elution step. This fraction was further 
Figure 9. Isolation Scheme of Compounds from Pochonia suchlasporia. Bioassay guided 
fractionation singled out three sub-fractions which yielded five compounds that were subjected 




separated using a stepwise gradient of methanol and water on an HP20ss column affording 4.0 g 
of an active fraction from 70% methanol in water. This subfraction was further subjected to 
separation via silica gel and monitored by TLC using a solvent system of dichloromethane and 
acetone. The major compounds were purified using reverse phase (C18) by HPLC with 0.1% 
formic acid in water and acetonitrile or water and methanol (Figure 9). Bond-line structures were 
determined through 1H, HSQC, HMBC, and COSY NMR and accurate mass data were obtained.  
A m/z 251 compound [M – H]- was purified from the DCM/acetone (19:1) fraction via 
semipreparative chromatography over Gemeni C18 at 60% MeOH in H2O and was consistent 
with the molecular formula C13H16O5. 1HNMR in deuterated methanol revealed only five 
resonances. One quartet integrated to a 1H, 3 singlets each integrated to 3H, and one doublet also 
integrated to 3H. The quartet was the farthest shift downfield at δ3.5, suggesting the presence of 
an electron withdrawing group and split by the doublet methyl. The singlet methyls had no 
neighboring protons. A 13C NMR spectrum was not collected, however, HMBC data were 
collected and showed 13C shifts of δ159.9, δ141.5, and δ110.2 ppm representing sp2 carbons that 
were consistent with a substituted aromatic ring with the resonance effects of oxygen π donation 
causing the oxygen substituted carbons to shift further up field and the methyl substituted 
carbons to shift downfield. The substituted aromatic ring system accounted for 4 units of 
unsaturation and 6 carbons, leaving 2 units of unsaturation and 3 carbons unassigned to methyls. 
During the dereplication of the remaining proton shifts, the two methyls upfield of δ1.7 ppm 
suggested a double bond was unlikely; therefore, the most likely functional groups would be a 
carbonyl and another ring. Due to the number of oxygens, an ester functionality was proposed, 




δ5.0 ppm. The proposed structure was confirmed to be sclerotinin A by a comparison to 
literature values.103 (-)Terpestacin was also dreplicated according to literature.104 
A m/z 419.2055 compound [M + H]+ was isolated from a DCM/Acetone (10:1) fraction 
via preparative HPLC (Gemini C18) at 55% MeOH in H2O for 4 minutes followed by a gradient 
of 55-80% over 16 minutes and a wash of 80-100% over 1 minute. The mass data were 
consistent with a molecular formula of C23H30O7 and had an unsaturation number of 9. Asteltoxin 
was dereplicated via literature by comparing 1H NMR and 13C NMR values.105 
A m/z 403.2109 compound [M + H]+ was isolated from a DCM/Acetone (19:1) fraction 
via preparative HPLC (Gemini C18) at 55% MeOH in H2O for 4 minutes followed by a gradient 
of 55-80% over 16 minutes and a wash of 80-100% over 1 minute. The mass data were 
consistent with a molecular formula of C23H30O6 and an unsaturation number of 9. AB5529 was 
dereplicated according to literature.106 
A m/z 425.2671 compound [M + Na]+ was isolated from the DCM/acetone (19:1) fraction 
via semipreparative chromatography over Gemeni C18 at 55% MeOH in H2O for 4 min followed 
by a gradient of 55-80% over 16 minutes, and was consistent with the molecular formula 
C23H30O6 and was not consistent with any structure in the literature. From the molecular formula, 
an unsaturation number of 9 was calculated. The structure was elucidated using a combination of 
1H NMR, 13C NMR, COSY, HSQC, and HMBC. A shift of 162.2 ppm (C-1) suggested a 
carbonyl was present. There was a HMBC correlation between the carbonyl (C-1) and a proton 
singlet integrating to 1 at 7.23 ppm, which was determined to be an aromatic proton (H-3). 
Proton H-3, had HMBC correlations to two singlet methyls at 12.0 ppm and 16.8 ppm (C-22 and 
C-23) as well as a quaternary carbon at 152.3 ppm (C-5). HMBC correlations between the 




and 113.4 ppm (C-2 and C-4), which afforded a substructure of a dimethylated pyrone. There 
was an additional HMBC correlation from C-5 in the substituted pyrone unit with a doublet 
proton, integrating to 1 at 6.57 ppm (H-6). HSQC of the H-6 to 121.7 ppm (C-6) suggested an 
olefin, and a J coupling of 15.0 Hz from 1H NMR suggested a trans olefin. Using COSY and J 
couplings of the associated protons (H-7 to H-9, 15.1 to 15.3 Hz), carbons C7-C9 were 
determined to be a dienyl moiety in the trans configuration for both olefins. COSY correlations 
further connected H-9/H-10, H-10/H-11, H-11/H-12, and H-12/H-13, such as was seen in both 
asteltoxin and AB5529, however, C-10 had a 13C shift of 81.0 ppm instead of 132.5 ppm 
signifying the reduction of the sp2 carbon to sp3. The two possible substitutions would be either 
an epoxide, or a furan ring via ether connection between C-10 and C-13. The carbon shifts of C-
10 and C-11 (81.0 ppm and 77.3 ppm respectively) were more consistent with a furan ring 
system than an epoxide (expected shifts 40-65 ppm), similar to what was determined in the 
revision of asteltoxin B.105 The remaining 13C NMR and 1H NMR shifts corresponded closely to 
the literature shifts of the bicyclic ring system of asteltoxin and AB5529 as well the literature 












Table 1. NMR Spectroscopic Data (600 MHz, DMSO-d6) for Asteltoxin and Derivatives 
 AB5529 Asteltoxin Asteltoxin G 
Position 13C 1H (J in Hz) 13C 1H (J in Hz) 13C 1H (J in Hz) 
1 162.2  170.5  162.2  
2 123.4  89.2 5.58, s 123.7  
3 145.4 7.22, 2 162.4  145.7 7.23, s 
4 113.3  108.4  113.4  










(J=15.0, 11.1) 135.3 
6.96, dd 





(J=14.9, 10.8) 132.0 
6.47, dd 





(J=14.9, 10.8) 137.8 
6.63, dd 





(J=15.3, 10.7) 132.5 
6.33, dd 
(J=15.3, 7.2) 81.0 4.2, t (J=8.1) 
11 132.7 
5.94, dd 
(J=15.3, 7.4) 134.5 
5.96, dd 





(J=7.6, 3.2) 84.4 
4.48, dd 
(J=7.2, 3.0) 86.6 4.57, t (J=3.8) 
13 84.6 
4.12, dd 
(J=9.5, 3.9) 78.8 3.56, s 87.1 
4.11, d 
(J=3.5) 
14 61.7  61.7  62.1  
15 79.8  79.8  79.2  
16 89.4 
3.55, dd 
(J=6.1, 3.3) 89.3 
4.12, dd 
(J=9.1, 3.6) 91.3 
3.85, dd 
(J=9.0, 4.0) 
17 21.9 1.27-1.48, m 21.9 1.31-1.43, m 22.6 1.32-1.45, m 
18 11.8 0.86, t (J=7.2) 11.8 0.86, m 12.1 0.88, t (J=7.4) 
19 111.6 5.00, s 111.9 5.00, s 113.7 5.22, s 
20 18.2 1.16, s 18.2 1.15, s 19.1 1.16, s 
21 16.4 0.99, s 16.4 0.99, s 15.3 0.9, s 
22 18.2 1.99, s 9.1 1.89, s 15.0 2.00, s 
23 14.9 1.93, s 57.1 3.79, s 16.8 1.94, s 
15OH  5.1, d (J=6.1)  
5.11, d 
(J=6.1)  5.12, s 
13OH  4.23, s  4.23, s   






Figure 10. ROESY Correlations of AB5529 and New Derivative Asteltoxin G. Atom labels 
shown in parentheses. 
 
Since only the planar structure of AB5529 was present in the literature, ROESY was used 
to determine the relative configuration of both AB5529 and asteltoxin G. AB5529 was found to 
have the same relative configuration of asteltoxin based on the ROSEY correlations of H-12, H-
13 and H-19 to the H-21. On the opposite face of the molecule, H-16 and the hydroxyl on C-13 
correlated to H-20. For the new compound, asteltoxin G, the H-21 proton was correlated to the 
H-12, H-13, and H-19 (Figure 10). A correlation between H-11 and H-12 gave the relative 
configuration of the hydroxyl on C-11. On the opposite face of the molecule, H-20 was 
correlated to the H-10 and H-16. The seemingly long-range correlation between H-20 and H-10 
was possible due to the concave nature of fused furan rings (Figure 11). These correlations also 





Figure 11: 3D Rendition of Asteltoxin G. The image is centered on the H-10 which is facing 
out from the plane of the page. Directly below it, is the methyl C-20. 
 
Since the only differences between AB5529 and asteltoxin involved the C-2 and C-3 sp2 
carbons on the pyrone ring, and the relative configurations were the same, the optical rotation 
values could be compared between the two. This is because circular light, a photon with its own 
electromagnetic field, can be affected by the electromagnetic field of each atom/bond within a 
molecule. Therefore, differences in electron density of chiral centers can have different effects 
on circular light. Since sp2 carbons are planar, there is no potential chirality therefore there is no 
difference in electron density that would change the angle. Both AB5529 and asteltoxin had 
positive optical rotations ([α] +28 and [α] +20), therefore AB5529 is predicted to have the same 
absolute configuration. Asteltoxin G, however, had extra chiral centers meaning that the optical 
rotation could not be directly correlated. Calculated optical rotations were determined using DFT 




experimental optical rotation of asteltoxin G was found to be [α] +48 (c 0.1, MeOH), suggesting 
that the absolute configuration of asteltoxin G is as show in 1b (Figure 12). This correlates with 
the absolute configuration of the two furanose rings on asteltoxin and AB5529. It is important to 
note that large differences in the magnitude of specific rotations between DFT and experimental 
calculations are expected as discussed in published evaluations of DFT.107 Differences in 
magnitudes can occasionally be affected by the quality of the basis set used, but as molecules get 
more complex with more degrees of freedom, either exponential time or smaller basis sets are 
necessary to calculate specific rotation.  
 
Figure 12. Possible Configurations of Asteltoxin G. Each enantiomer was examined via 
computational analysis to determine the absolute configuration of the isolated compound 
asteltoxin G. 
 
Mosher analysis was unsuccessful due to the addition of base causing compound 
degradation. CD (circular dichroism) analysis was also unsuccessful. Like optical rotation, CD is 
dependent on the molecule influencing light, however CD uses the difference in right-handed 
and left-handed circularly polarized light while polarimetry utilizes linearly polarized light.108 
For CD to be easily detected, a chiral center needs to be sufficiently near a source of absorption 
such as a chromophore (eg., a π → π*).108 When not sufficiently near a chromophore, as was the 




 An alternative support for the absolute configuration of asteltoxin G can use biosynthesis 
information. While there is precedent in the literature for fungi producing enantiomers of natural 
products, this combined with DFT calculations makes the proposed absolute configuration of 1b 
(Figure 12) for asteltoxin G more likely. Asteltoxin, and therefore its analogs, are formed by 
polyketide synthetase. 13C studies have determined that the carbon source of asteltoxin is from 
acetate and the methylation is theorized to be from methionine. The biosynthesis (Figures 13-14) 
is hypothesized to occur when acetate is formed into to acetyl CoA or propionyl-CoA,109,110 
modified into malonyl CoA via acetyl CoA carboxylase, elongated by the Claisen condensation 
and then depending on the location on the molecule, is reduced first by a ketoreductase followed 
by a dehydrase to form the olefins with the proper E/Z conformation to give the C18 polyketide 
seen in Figure 14.111,112 The pyrone is formed by a nucleophilic attack on the enol thioester 
attaching the polyketide to the enzyme to release it.111 Epoxides are formed by mono-oxygenases 
followed by nucleophilic attack of water to afford the compounds.111 It is reasonable to assume 
that asteltoxin G can be formed by the mono-oxygenase epoxidizing the next olefin so that as the 
compound is undergoing cyclization for form the bicyclic furan ring, it cyclizes and additional 





Figure 13: Proposed Asteltoxin Biosynthetic Mechanism. Following polyketide backbone 
formation, a mono-oxygenase epoxidizes key olefins which is then nucleophilically attacked by 






Figure 14. Proposed Biosynthetic Mechanism for Asteltoxin G. During the epoxidation by 
mono-oxygenase, an additional olefin is epoxidized so that during the during the furan 
cyclization, a tricyclic ring is formed instead of a bicyclic ring. 
 
4.4.3 Pure Compound Assays 
 Initial monolayer assays determined that sclerotinin A did not have enough cytotoxic 
activity to warrant further interest (>50 µM against 3T3 mouse fibroblasts, and >50 µM against 
Panc-1 cells). (-)-Terpestacin, had slight selectivity against Panc-1 cells compared to the 3T3 
mouse fibroblasts (LC50 values of 28.5 µM and 39 µM, respectively), but it had been 
investigated by others so was not chosen for further study.24  
The selectivity indices of the three asteltoxin compounds were calculated (Table 5) by 
dividing the LC50 of normal cell lines by the LC50 of cancerous cells lines to create a value that 




potential cytotoxicity to normal cell lines.113 For these indices, the larger the number, the more 
potent the compound was at targeting the cancer cells versus the normal cells. Asteltoxin was 
shown to have no selectivity with regard to NIH/3T3 cells and Panc-1 cells.  On the other hand, 
the LC50 values and selectivity of asteltoxin G against Panc-1 and MIA PaCa-2 monolayer assays 
were quite promising, showing potency in the pancreatic tumor lines and relative safety in the 
mouse fibroblast and normal pancreas lines (Figures 15-18, Table 3). Most notable was the fact 
that the normal lines retained their characteristic shape even at high doses of the compounds, a 
feature not shared by the tumor lines, which swelled and proceeded to die.  This was a rare 
occurrence in our screen, with most normal lines dying or becoming damaged in similar ways to 
the tumor lines when treated with other compounds or extracts, and made the compounds better 
candidates for lead compounds.  
 The compounds were tested further in the newly developed spheroid assay. Previous 
comparisons of the two assays in our lab have shown that a higher concentration, (~10x), is 
required to attain similar cytotoxicity in the spheroid assay compared to the monolayer assay. 
LC50 values were significantly increased for all of the compounds tested except asteltoxin G in 
the MIA PaCa-2 spheroid assay (Figures 19-22, Table 4).  Asteltoxin G showed an increase in 
potency in the tumor spheroid assay compared to the monolayer with a selectivity values of 
>15.6 for both the Spheroid NIH 3T3 and the hTERT-HPNE MIA PaCa-2 versus 2 to >8.3 in the 
monolayer assays, (Table 5), a result we had not previously encountered. No toxicity to the 
normal mouse NIH/3T3 fibroblast spheroids and the hTERT-HPNE spheroids was seen even at 
the highest concentration tested of 50 µM.  The MIA PaCa-2 spheroids treated with 6.25 µM of 
asteltoxin G for three days were one-third the size of DMSO control spheroids based on cell 




size compared to DMSO control at 6.25 µM. This showed that asteltoxin G was the most 
prominent drug lead of the isolated compounds as it might selectively target spheroid cells.  
 
Table 3. Cytotoxicity Values for Monolayer Assays. Normal cell lines are labeled in green, 























>50 NT >50 NT 
(-) 
Terpestacin 
39 NT 29 NT 
AB5529 >50 >50 >50 32 
Asteltoxin 4 >50 6.25 40 
Asteltoxin 
G 




Table 4. Cytotoxicity Values for Spheroid Assays. Normal cell lines are labeled in green, 








(LC50 in µM) 
Spheroid  
Panc-1 (LC50 in 
µM) 
Spheroid 
 MIA PaCa-2 
(LC50 in µM) 
Sclerotinin A >50 >50 >50 NT 
(-) Terpestacin >50 >50 36 NT 
AB5529 >50 >50 >50 32 
Asteltoxin >50 >50 >50 42 





Table 5. Selectivity Indices of Asteltoxin and Derivatives. NA= not applicable 
Selectivity AB5529 Asteltoxin Asteltoxin G 
Monolayer NIH 3T3/Panc-1 NA 0.6 2 
Monolayer NIH 3T3/MIA PaCa-2 >1.6 0.1 5 
Monolayer hTERT-HPNE/Panc-1 NA >8 >3.3 
Monolayer hTERT-HPNE/MIA PaCa-2 >1.6 >1.3 >8.3 
Spheroid NIH 3T3/Panc-1 NA NA NA 
Spheroid NIH 3T3/MIA PaCa-2 >1.6 >1.2 >15.6 
Spheroid hTERT-HPNE/Panc-1 NA NA NA 






Figure 15. Cytotoxicity Assays for the Asteltoxin Class Compounds in Monolayer Mouse 
3T3 Fibroblast Cells. Cellular density is show in green fluorescence. Asteltoxin shows 
consistent cytotoxicity up to 50 µM, AB5529 only showed slight cellular toxicity at 50 µM, and 





Figure 16. Cytotoxicity Assays for the Asteltoxin Class Compounds in Monolayer HPNE 
Cells. Cellular density is show in green fluorescence. Cytotoxicity was only noticed at the 





Figure 17. Cytotoxicity Assays for the Asteltoxin Class Compounds in Monolayer Panc-1 
Cells. Cellular density shown by green fluorescence; nuclei located by blue fluorescent. 
Asteltoxin shows decreased cellular density across all concentration ranges, while AB5529 






Figure 18. Cytotoxicity Assays for the Asteltoxin Class Compounds in Monolayer MIA 
PaCa-2 Cells. Cellular density is show in green fluorescence. Asteltoxin shows consistent 
cytotoxicity up to 50 µM, AB5529 started showing cellular toxicity beginning at 25 µM, and 







Figure 19. Cytotoxicity Assays for the Asteltoxin Class Compounds in Spheroid Mouse 3T3 
Fibroblast Cells. Cellular density shown by green fluorescence; nuclei located by blue 






Figure 20. Cytotoxicity Assays for the Asteltoxin Class Compounds in Spheroid HPNE 
Cells. Cellular density shown by green fluorescence; nuclei located by blue fluorescent. All 






Figure 21. Cytotoxicity Assays for the Asteltoxin Class Compounds in Spheroid Panc-1 
Cells. Cellular density shown by green fluorescence. Asteltoxin showed cytostatic activity, while 
AB5529 showed no noticeable cytotoxicity. Asteltoxin G showed decreased cellular density over 





Figure 22. Cytotoxicity Assays for the Asteltoxin Class Compounds in Spheroid MIA 
PaCa-2 Cells. Cellular density shown by green fluorescence; nuclei located by blue fluorescent. 
Cellular density decreased with all three compounds. Asteltoxin G was the most potent causing 




4.4.4 Stability of Compounds and Their Activity 
Compound degradation and loss of activity has been noted for other polyenic alpha 
pyrones such as citreoviridin.114 A cis-trans conversion of citreoviridin to isocitreoviridin, after 
as little as 30 minutes light exposure, resulting in a significant decrease in their anticancer 
activity.114 The polyenic motif itself is known to degrade in light, as is also seen in beta-
carotene,115 first through a cis-trans isomerization followed by a singlet diradical116 which then 
degrades into other compounds. Since, the location of the initial isomerization of the degradation 
of beta-carotene is theorized to be non-specific along the polyenic chain,116 it can be logically 
construed that a longer polyenic chain affords more opportunities for the initiation of 
degradation. Since asteltoxin G has fewer olefins and more steric hindrance for a cis-trans 
isomerization, it was hypothesized that the degradation of asteltoxin should therefore be 
inhibited.  
Bioassays were repeated to confirm the activity of the metabolites; however it is possible 
that rearrangements could occur during the assay itself.  To test the relative stability of 
asteltoxin, AB5529 and asteltoxin G, the compounds were dissolved in DMSO at 0.1 mg/mL and 
placed in front of a 60w GE tungsten lightbulb for 0 to 600 minutes.117 Samples were then 
analyzed by LC-MS to determine the relative purity. Asteltoxin began degrading within 5 
minutes, while asteltoxin G only showed slight degradation even when exposed for up to 600 
minutes (Appendix Figure A24). Since AB5529, which shared the same pyrone motif as 
asteltoxin G and the polycyclic furanose group as asteltoxin, also degraded rather quickly, the 
increased stability of asteltoxin G may be able to be attributed to the tricyclic furanose ring, 




While degradation rate could explain the increased activity of asteltoxin G in a spheroid, 
it is not the only possible explanation. Alternative hypothesis could include different molecular 
targets between asteltoxin and asteltoxin G, spheroid permeability, cell permeability, or 
increased uptake.118 Additionally, the increased in vivo like state , the cell-cell interactions, and 
signaling of the cells within the spheroid assay may make a completely different mechanism 
responsible for the observed results.118 
 
4.5 Conclusion: 
In summary, asteltoxin analogs as well as a benzophenone and (-) terpestacin were 
isolated form the fungus Pochonia suchlasporia after its crude extract was found to have 
selectivity towards MIA PaCa-2 and Panc-1 pancreatic ductal adenocarcinoma cell lines over 
NIH/3T3 normal mouse fibroblasts and hTERT-HPNE cell lines. The benzophenone, sclerotinin 
A was found to be inactive at the concentrations tested, and the (-) terpestacin had activity 
consistent with a literature report.104 Among the three asteltoxin analogs, AB5529 only achieved 
and LC50 of below 50 µM for one cell line (MIA PaCa-2), while both asteltoxin and asteltoxin G 
had LC50 values below 50 µM for 3 out of 4 of the cell lines. The selectivity indices for 
asteltoxin, asteltoxin G, and AB5529 were calculated and asteltoxin was found to have 
monolayer selectivity indices lower than 1 for the NIH 3T3 cells compared to both the Panc-1 
and the MIA PaCa-2 cell lines, which means that it was more cytotoxic to the non-cancerous cell 
line than the cancerous cell lines. The monolayer selectivity indices of asteltoxin were greater 
than 1 for the hTERT-HPNE cells line versus the both the Panc-1 and MIA PaCa-2 cell lines, 
which means it was less cytotoxic to the non-cancerous cells. Asteltoxin G, however, had 




cancer lines over the non-cancer lines in all cases. The pure compounds were also subjected to a 
3-D spheroid assay which better mimics the in vivo conditions of pancreatic cancer tumors. Two 
compounds retained their selectivity within the spheroid assay, (-) terpestacin and the new 
analogue asteltoxin G with values of  >1.3 and >15.6, respectively.  
     
4.6 Experimental: 
4.6.1 Small Scale Screening of Soil Samples  
Soil samples were briefly washed, diluted with water and plated on a variety of media 
and growth conditions.119 Purified fungal isolates were grown in small scale solid-state 
conditions with a medium composed of three autoclaved Cheerios™ in a test tube and 1800 µL 
of a sterile sucrose water (2 g/L) with 0.05 mg/L of chloramphenicol.  After growing for four 
weeks, test tubes were partitioned twice with 2 mL of ethyl acetate using a liquid partitioning 
robot.  Ethyl acetate partitions were evaporated under vacuum, dissolved in 500 µL DMSO and 
submitted for assay.  A total of 3,588 fungal extracts were tested by using a 0.5 µL pin tool and 
tested in both tumor and normal cell lines at a concentration of 10 µg/mL. Cell viability was 
determined by MTT assay when the project began but evolved later to use live cell area 
determination using the Operetta, which we found to correlate well with MTT values (r2=0.9, 
data not shown).  Follow-up screening regrows for confirmation of activity were done in 250 mL 
Erlenmeyer flasks and grown for the same period of time prior to extraction. 
 
4.6.2 Large Scale Regrow of Small Scale Hit 
Once the activity was confirmed, a large scale grow-up was initiated in three large 




fifty 1 L Erlenmeyer flasks. 850mL of 9.52 g/L sucrose water with 0.15 g/L chloramphenicol 
were added to 500 mL autoclaved Cheerios™ in each bag. The fungi were grown for 4 weeks 
and extracted with ethyl acetate three times overnight to get the initial crude extract.  
 
4.6.3 Fungal Isolation and Identification  
The fungus studied here was isolated from Gelzan Czapek agar and named internally 
“Mt. Hood-5 Gelzan-5.”  The fungus was discovered in a soil sample obtained near Mount Hood, 
Oregon.  PCR was performed with the ITS1 and ITS4 primers and products sent to the Biology 
Core Molecular Lab at OU for ITS sequencing.  The results indicated a 99% max identity to 
Pochonia suchlasporia, when compared to NCBI BLAST. 
 
4.6.4 Compound Isolation 
The crude extract (89g) was initially fractionated by a stepwise gradient consisting of 
hexanes, dichloromethane, and methanol over a silica column. The active fraction, 4.0 g, from a 
9:1 dichloromethane:methanol condition, was further subjected to chromatography using a 
stepwise gradient of methanol and water over a HP20ss column. The 70% methanol in water 
subfraction was selected for further separation over silica based on conditions selected by TLC. 
A solvent system of dichloromethane and acetone over silica was chosen as it had the best 
resolution, and the separation was monitored by TLC. Further fractionation was carried out using 
preparative HPLC (Shimadzu, Gemini C18 column - 250 mm x 10.1mm, 5µm, Phenomenex) 
with a gradient of MeOH and H2O and a semi-preparative HPLC (Waters, Gemini C18 column - 
250 mm x 21.2 mm, 5µm, Phenomenex) using either isocratic or gradient conditions (see 




column – 3.0 mm x 75 mm, 2.6 µm, Phenomenex) with a 0.1% formic acid in water to 
acetonitrile gradient (10:90 to 100). Planar structures were determined through 1H, HSQC, 
HMBC, and COSY NMR (Varian Unity Inova 600 MHz) and mass data were on a HRESIMS 
(Agilent 6538 high mass resolution QTOF MS and Agilent 1290 HPLC). Optical rotation values 
were determined using an AUTOPOL III automatic polarimeter. When applicable, NMR data 
and optical rotation were compared to literature values. ROSEY NMR was used for relative 
configuration.  
 
4.6.5 Calculation for Absolute Configuration of Asteltoxin G 
Structure confirmations were minimized using DFT calculations using aug-cc-pVDZ 
basis set in MeOH solvent conditions. The resulting minimized structures were subjected to 
polar=optrot command using b3lyp/3-21g basis set in Gaussian 09..  
 
4.6.7 Monolayer Cytotoxicity and Selectivity Assays 
Monolayer mammalian cell assays were performed as described previously120 and 
viability determined by MTT assay121 or by a Calcein AM and Hoechst 33342 live cell area 
assay on the Perkin Elmer Operetta using the 10x objective.  This assay was performed by 
adding to each well 5 µL of a 1:5 dilution in PBS of a 40 µM calcein AM and 160 µM Hoechst 
33342 DMSO stock, incubating the plate for 30 minutes at 37°C and recording data from the 
Operetta.  Harmony software was used to calculate the live cell area by finding all Hoechst-
labeled nuclei and then assigns live or dead assessments to each cell based on a predetermined 
threshold of green fluorescence.  Live cells are those with esterases still capable of cleaving the 




4.6.8 Spheroid Cytotoxicity and Selectivity Assays 
 Spheroid cytotoxicity assays were performed using a modification of the published 
protocol from the Eccles group.122 Cell lines were trypsinized and seeded at 1,000 cells per well 
(250 cells per well in MIA PaCa-2 due to more rapid growth in this cell line that would overgrow 
the field of view) in 100 µL of the appropriate cell media into Ultra Low Attachment 96-well 
plates (Corning Cat. # 7007). Spheroids were grown for four days in a humidified 37 ºC 5% CO2 
incubator.  At day four, cells were treated with compounds dissolved in DMSO.  Final DMSO 
concentration in the well was 0.5%.  The spheroids were grown for an additional three days in 
the incubator, then analyzed using the same calcein AM and Hoechst assay used in the 
monolayer assay, and all images were recorded on the Operetta using the 10x objective.  
Harmony software was used to calculate the live cell area for each spheroid.   
 
4.6.9 Compound Degradations Study 
 A lamp fitted with a 60w GE tungsten filament lightbulb was placed 6 inches from 3 vials 
each containing 100 µL of 0.1 mg/mL of either asteltoxin, AB5529, or asteltoxin G. The samples 
were analyzed by LCMS after the total light exposure times of 0, 5, 15, 30, 60, 180, and 600 







Chapter 5: Antifungal Cyclic Peptide from Sphaceloma corylii 
5.1 Abstract 
A leaf is composed of more than just plant cells. There are also microorganisms 
inhabiting the intercellular tissues. that can be either benign or pathogenic to the host plant. The 
benign microorganisms, called endophytes, can work in an symbiotic fashion providing 
secondary metabolites used by the host plants for nutrients or defense against other pathogenetic 
microorganisms.53–55 Due to the defensive nature of some of these endophytes, we theorized that 
they might contain new antifungal secondary metabolites that would be safe to use agriculturally. 
 Isolating endophytes from other organisms that reside within the host plant can be a 
difficult and time-consuming process. To incorporate this process into a high throughput 
environment, a modified laser device was created to cut squares from pre-sterilized poplar 
leaves. These squares were released into a 96-deep-well plate with agar and the resulting 
colonies were isolated on small Petri plates.  
One isolate was noted for a unique morphology and fungicidal activity and was therefore 
chosen for further analysis. Subsequent ITS sequencing and morphological analyses determined 
the organism was a Sphaceloma coryli, a species previously noted only in relation to a hazelnut 
blight,123 however its teleomorph of the Elsinoë genus has been known to be pathogenic to other 
hosts such as mangos and avocados.124 Using bioassay guided fractionation, 3 nine-residue 
peptides were isolated and named persephacins A-C. Also isolated were 3 elsinochromes, A, D 
and a new analogue E, which were found not to be responsible for the bioactivity. The bioactive 
persephacins were tested for their suitability as an agriculture antifungal through infiltration, 





 The isolation, purification, and identification of Sphecaloma were completed by the 
endophyte team led by Dr. Shikha Srivastava and the initial chemical extraction of the fungus, 
initial isolation of the elsinochromes and the isolation of persephacin A were completed by Dr. 
Saiket Haldar. Structure elucidation was completed by Allison Mattes in conjunction with both 
Dr. Saiket Haldar and Dr. Lin Du. Both in vitro and in vivo assays reported here were completed 
by Dr. Shikha Srivastava. Assay quantification and media optimization experiments were 
performed by Allison Mattes. 
 
5.3 Introduction 
Within a leaf, there is much more than just plant cells and nutrients. Residing among the 
“internal tissues of plants beneath the epidermal cell layer, where they colonize healthy and 
living tissue via quiescent infections”52 are the cells of other organisms called endophytes. These 
quiescent infections do not necessarily extend to the for the entire duration of the organism’s life 
and at some point they may turn pathogenic.53–55  When in symbiosis, endophytes have been 
known to benefit plant growth by providing secondary metabolites that  provide nutrients or 
signaling specific growth conditions.53–55  Their largest noted effect, however, is the control of 
other pathogenic microorganisms.51  
This noted effect of microbial defense has made endophytes an interest as a new frontier 
of natural products drug discovery.48–51 Research into endophytes have already produced results 
including secondary metabolites with antimicrobial activities that have spanned across a broad 
range of classes, from terpenoids to peptides.51 In this chapter, we decided to use the defensive 




nature of some of these endophytes, they might serve as a source of secondary metabolites with 
antimicrobial applications that would be safe to use agriculturally. 
Why are antimicrobial agricultural compounds an important area of research? While not 
the most prestigious target of anti-microbial compounds, diseases to agricultural plants account 
for approximately 16% of losses125 translating into an approximate global financial loss of $540 
billion.126 In addition, noted agricultural resistances mechanisms have been theorized to either 
forecast or induce drug resistances in the clinical setting. This is being questioned, especially in 
Europe, where the key agricultural antifungal is azole based and there has been an increased 
occurrence of azole-resistant microorganisms appearing as human pathogens.127 This theory is 
founded on the concept that, the selective elimination of species at the agricultural level allow 
those that have resistance to dominate the landscape.127 As the antibiotic resistant organisms 
begin to comprise the majority of microbes in the treated soils, the chance of a resistant 
pathogenic species infecting a human host increases.127 For this reason, it is important that 
antimicrobials with different modes of action be applied at varying times to agricultural crops, 
and therefore it is important to isolate new compounds with these new modes of action. 
One of the important classes of compounds being considered as agricultural antimicrobial 
compounds are peptides due to their potential for reducing toxicity and having minimal 
environmental impact that can meet newly strengthened regulations imposed by European and 
US governments.125 To date, over 900 antimicriobial peptides have been identified.125 Those that 
are produced non-ribosomally can have a variety of alterations, including non-proteogenic amino 
acids, N-methyllation, and cyclization, all of which can prevent proteolysis.125 
One peptide known for antimicrobial, specifically antifungal, activity is aureobasidin A. 




aureobasidin A is theorized to target growing cells by causing unusual actin distributions and 
preventing mitosis.128 While useful in laboratory experiments, this antifungal has not seen 
clinical applications currently due to resistance genes already found, 128 however further analysis 
has found that the aromatic phenylalanine in the aureobasidin is a target for an efflux pump in 
the resistance mechanism.129  
Assay-guided fractionation of an extract from the Spaceloma endophyte discussed in this 
chapter resulted in the compound isolation and structure elucidation of three new peptides 
(Figure 23), similar to aureobasidin, but in place of the phenylalanine, a new aliphatic amino acid 
was found. These new peptides have the potential for antifungal activity that evades resistance 
mechanisms. We analyzed these compounds for applicability as an agricultural antifungal via 
infiltration assays. 
 
5.4 Results and Discussion 
5.4.1 Selection and Identification of Isolate  
Under the premise that endophytic fungi might be an excellent source of new antifungal 
compounds for use in agriculture systems,48–51 a way to efficiently isolate endophytes without 
contaminating the isolates with surface-dwelling fungi was explored. The greatest source of 
contamination can occur from the cutting implements used to prepare leaf samples, therefore a 
cutting apparatus that minimizes transfer contaminiation in a high throughput manner was a 
primary advancement. Since commercially available lasers of higher power have become 
increasingly more available for the common consumer, we thought they might be advantageous 
for using as sterile incisions on leaves. Externally sterilized leaves were arrayed over a 96 well 




the isolates were purified. During purification, an inhibition ring between two fungi. The 
inhibiting fungus was isolated and grown in PDB broth and extracted in ethyl acetate. The 
resulting extract was tested against Peyronellaea glomerate and showed 80% inhibition at 0.5 
mg/mL  
 The inhibiting fungus was identified through morphologically means and later confirmed 
by ITS sequencing as Sphaceloma coryli, a telemorph of Elsinoe.123 The general morphology 
formed irregular, strongly folded, compact and elastic colonies, however, it varied in appearance 
depending on the medium used. On MEA (malt extract agar), colonies were yellow to deep 
orange with a light color margin, wrinkled, raised on the sides with a mostly hollow (concave) 
center. However, on PDA (potato dextrose agar), colonies appeared purplish-red/brown with a 
yellow ochre margin. The colonies were raised, wrinkled surface and elastic on the reverse side 
of the plate.  
 
5.4.2 Compound Isolation and Structure Determination 
 Few compounds have been purified from the genus Sphaceloma: elsinochrome C1, a 
dithiofatty acid, and a steroidal compound; none of which have noted antifungal activity.130 
Therefore, this isolate showed exceptional promise to yield new natural products    
The initial extraction was completed using the fungus grown in 15 flasks of PDB media. 
An extract was prepared by ethyl acetate partitioning followed by bioassay guided fractionation. 
Initial prefractionation occurred by VLC column chromatography on HP20ss with MeOH and 
H2O in a stepwise gradient. Afterwards, HPLC using both C18 and biphenyl columns was used 
to purify three rich red colored compounds, which were determined to be elsinochromes. 




NMR data with the literature values, however, elsinochrome D did not have a designated relative 
configuration.131,132 The new analogue, elsinochrome E showed similarities to the planar 
structure of elsinochrome D, except with one of the secondary hydroxyls was oxidized to a 
ketone. Relative configuration was not determined on this compound as it was not biologically 
active. 
  





The bioactive compound was found to not be an elsinochrome. Accurate mass was 
carried out on the major active compound yielding an ion at m/z 1097.7586 [M + Na]+, which 
gave a molecular formula of C57H102N8O11. To elucidate the structure, 1H, 13C, HSQC, HMBC, 
and COSY NMR were completed on the compound (Table 5). The 1H NMR revealed three 
doublets between 8.0 and 9.0 ppm suggesting amide protons and 4 singlets integrating to 3 
between 3.0 and 3.5 ppm reminiscent of methylated amides. There were also 9 carbonyl shifts 
according to the 13C NMR. Between the mass data, the number of carbonyls, and the number of 
amide/methylated amides, it was determined that the compound was likely a peptide with 7-9 
residues. A key feature of peptides is that each residue is isolated in a spin system by the 
carbonyls, and there is an NMR experiment called TOCSY which can correlate all protons 
within a spin system. To determine the confirm the presence of a peptide as well as the number 
of residues, a TOCSY was run on the sample in addition to the other NMR experiments. The 
TOCSY results showed 9 distinct spin systems further confirming the identity of the compound 
as a peptide and the number of residues.  
 
Table 1. NMR Shifts of Persephacins A,B,C 
 Persephacin A Persephacin B Persephacin C 
Position 13C 1H  13C 1H  13C 1H  
OH-ILE       
1 73.13 5.73 74.31 5.73 73.46 5.66 
2 36.48 1.92 37.62 1.92 36.31 1.92 
3 22.99 1.14,1.57 23.97 1.14, 1.57 23.00 1.15, 1.58 
4 10.35 0.85 11.53 0.86 10.39 0.84 
5 14.91 1.06 15.95 1.06 14.83 1.06 
6 169.20  169.20  169.47  
N-Me-
Val       




8 61.58 5.02 62.66 5.00 61.42 5.05 
9 27.66 2.21 28.77 2.20 27.84 2.21 
10 10.21 0.85 19.73 0.82 10.26 0.85 
11 19.02 1.01 20.11 1.00 19.23 1.00 
12 169.85  169.86  170.03  
Per       
NH  8.49  8.49  8.48 
13 45.56 5.28 46.61 5.27 45.45 5.29 
14 38.99 1.26, 1.98 40.03 1.26, 1.98 38.77 1.25, 2.03 
15 22.39 1.33 22.39 1.33 20.35 1.09 
16 19.58 0.91 20.59 0.91 19.47 0.93 
17 45.94 0.93, 1.24 47.03 0.93, 1.24 46.05 0.95, 1.24 
18 27.08 1.60 28.26 1.60 19.19 0.85 
19 18.85 0.85 20.22 0.86 19.16 0.86 
20 44.83 0.87, 1.24 45.90 0.87, 1.24 44.95 0.89, 1.24 
21 31.47 1.42 32.59 1.42 31.47 1.42 
22 19.95 0.84 21.02 0.84 19.70 0.84 
23 25.14 1.11.12,1.462 27.41 0.94, 1.02 24.96 1.11, 1.43 
24 11.53 0.97 12.51 0.97 11.43 0.97 
25 172.15  172.15  172.15  
N-Me-
Gly       
26 37.95 3.39 39.07 3.38 37.95 3.39 
27 51.40 3.40, 4.48 52.46 3.40, 4.48 51.40 3.40, 4.48 
28 169.09  169.09  169.09  
Pro       
29 23.31 1.94, 2.07 24.41 1.94, 2.07 23.31 1.94, 2.07 
30 29.58 2.15 30.64 2.15 29.58 2.15 
31 46.50 3.66, 3.99 47.60 3.66, 3.99 46.50 3.66, 3.99 
32 59.89 4.60 61.09 4.60 59.95 4.59 
33 172.39  172.39  172.34  
Ile       
NH  8.00  8.00  8.00 
34 54.32 4.68 55.34 4.67 54.33 4.65 
35 36.91 2.29 38.04 2.29 36.90 2.29 
36 14.82 1.01 15.90 1.00 14.90 1.00 
37 28.65 1.08 29.90 1.08, 1.39 28.79 1.08, 1.39 




39 172.64  172.64  172.69  
N-Me-
Val       
40 30.00 3.22 31.06 3.21 29.91 3.23 
41 61.48 5.28 61.83 5.31 61.38 5.24 
42 25.47 2.25 33.50 1.97 25.44 2.25 
43 17.50 0.81 14.81 0.78 17.66 0.81 
44 18.51 0.94 25.92 0.99, 1.11 18.36 0.93 
45 170.50  170.50  170.23  
58   12.01 0.92   
Leu       
NH  8.06  8.06  8.07 
46 47.52 4.94 48.57 4.94 47.55 4.87 
47 42.27 1.36, 1.69 43.51 1.36, 1.69 41.69 1.29, 1.71 
48 24.84 1.53 25.93 1.52 24.93 1.49 
49 22.32 0.96 23.53 0.95 22.63 0.94 
50 21.00 0.99 22.21 0.98 20.77 0.97 
51 172.37  172.37  170.23  
N-Me-
3-OH-
Val       
52 39.57 3.34 40.76 3.34 39.09 3.30 
53 71.65 3.80 72.79 3.80 30.08 2.86 
54 72.95  72.95  27.09 2.65 
55 27.04 1.30 28.21 1.30 27.21 1.61 
56 26.23 1.36 27.31 1.36 18.69 0.99 
57 166.96  166.96  168.87  
OH       
 
Before identifying each residue, there were a few things to note. There were no shifts in 
the aromatic region for either the 1H or the 13C spectrum, eliminating the presence of any 
tryptophan, tyrosine, histidine, and phenylalanine residues. Additionally, there were only 7 
amide/methylated amide shifts detected in the 1H NMR, while it was determined there were a 
total of 9 residues. Therefore, two residues would likely be some combinations of prolines and 




The proton peak at 5.73ppm, showed strong TOCSY (Figure 24) correlations to 1.92 ppm 
and 1.06 ppm. HSQC correlations of these to peak signify carbon shifts at (C-2) 36.48 and (C-3) 
22.99 ppm respectively which were in opposite phases and allowed the determination of the C-2 
as a methine and C-3 as a methylene. These shifts would signify the residue as either an 
isoleucine or a leucine. Because C-2 was further downfield than C-3, it was determined to be the 
β-carbon of the amino acid, which would make the residue an isoleucine. HMBC correlations 
confirmed the remaining methyl shifts, however there was no correlations seen to either a 
protonated or methylated amine. It was concluded that this could possibly be a depsi-bond 
instead.  
For the second residue, there were TOCSY correlations of 2.21, 1.01, and 0.85 ppm. 
From HSQC, these residues all had the same phase and in combination with 1H NMR were 
determined to be a methine and two methyls respectively. The residue was identified as a valine. 
A third residue showed at least 4 TOCSY correlations with the amide proton at 8.49 ppm. 
According to HSQC phase data, these correlated to two methines, one methylene, and one 
methyl. These shifts did not suggest any of the proteogenic amino acids. For the time being it 
was assigned as an unknown amino acid. 
The fourth residue was determined to be glycine. It had no TOCSY correlations, but the 
α-carbon, which was determined by the carbon shift of 51.50 ppm, was a methylene as 
determined by both 1H NMR integration and HSQC phase. 
The fifth residue determined had 5 TOCSY signals correlating to 4.60 ppm α-proton, all 
between 1.94 and 3.99 ppm. HSQC phase determination of the shifts showed that they belonged 
to 3 methylenes two of which had J couplings of 8 Hz. Both the 1H NMR and the 13C NMR 




 For the sixth residue, there were 3 easily apparently TOCSY correlations to the 4.68 ppm 
α-proton, and one weaker correlation at 1.44 ppm. HMBC correlations confirmed the weaker 
correlation. According toe HSQC phase data, there were 3 methines/methyls and 1 methylene, 
which suggested either a leucine or an isoleucine. The 2.29 ppm methine (H-35) had the 13C shift 
furthest downfield making it the β-carbon of the amino acid and therefore an isoleucine. 
The seventh residue identified had 3 TOCSY correlations to the 5.28 α-proton. HSQC 
phase data showed that all 3 atoms were methine/methyls. The residue was therefore determined 
to be a valine. 
The eighth residue identified had 5 strong TOCSY correlations to the 8.06 ppm amide 
proton. An additional TOCSY correlation was seen between the 4.94 ppm α-proton and 1.53 
ppm (H-48). The 1.36 and 1.69 ppm methylene (H-47) had the 13C shift furthest downfield 
making it the β-carbon of the amino acid and therefore a leucine. 
The ninth residue identified had two strong TOCSY correlations at 1.30 and 1.36 ppm. 
Upon investigation with HMBC, correlations were observed between the 3.80 ppm α-proton and 
a 13C signal at 72.95 ppm (C-54). The 72.95 ppm signal had no corresponding HSQC signal 
suggesting a quaternary carbon. These signals were not consistent with any of the 20 proteogenic 
amino acids, however hydroxy substitutions on quaternary hydrocarbons typically cause 13C shift 
of around 70-80 ppm. Therefore, the amino acid was determined to be the N-Me-hydroxy-valine. 
configuration of the common amino acids N-Me-Val, Ile, and Leu as N-Me-L-Val, L-Ile, and L-
Leu (Appendix Figures A61-A62). HMBC correlations were used to assemble the backbone of 
the peptide by correlating the shifts of alpha carbons, amide protons, and methylated amides to 
their nearby carbonyls. One alpha proton, showed correlations to two carbonyls, but one of these 




carbon was determined to belong to an isoleucine residue (C-1), however its carbon shift was 
further downfield than one would expect: being at 73.13 ppm. In comparison, there was another 
isoleucine residue in the same molecule and the alpha carbon had a 13C chemical shift of 54.32 
ppm. This suggested that the more shielding ester moiety was present instead of an amide, which 
would make the compound a depsipeptide and accounted for the lack of the second amide 
proton.  
In summary, TOCSY, HMBC, and HSQC analysis confirmed the presence of two N-Me-
valine residues, a N-Me-glycine residue, a leucine residue, an isoleucine residue, and the unusual 
N-Me-3-OH-valine residue. Using HMBC correlations of the α-atom to either the amide 
proton/methyl yielded the following order: OH-Ile-N-Me-Val-unknown residue-N-Me-Gly-Pro-
Ile-N-Me-Val-Leu-N-Me-3-OH-Val. Marfey’s analysis was used to determine the absolute 
configuration of the common amino acids N-Me-Val, Ile, and Leu as N-Me-L-Val, L-Ile, and L-
Leu (Appendix Figures A61-A62). 
The scaffold described above accounted for  46 C, 79 H, 8 N, and 11 O. This meant the 
remaining residue consisted of 11 C and 23 H according to the molecular formula C57H102N8O11. 
Using the phase sensitive nature of HSQC, it was determined that there were 4 methyls, 4 
methylenes, and 3 methines remaining. The proton on the alpha carbon showed as a triplet 
meaning the adjacent carbon was a methylene, however the splitting patterns and coupling 
constants for other protons were unable to be distinguished. Using the HMBC correlations shown 











Figure 25: HMBC Correlations of the New Amino Acid Residue, Persephanine. 
 
 While optimizing growth conditions, two analogues of persephacin were isolated in 
relatively minor amounts (Appendix Figure A26 for isolation scheme), 1.5 mg for persephacin B 
and 8 mg for persephacin C. The planar structure of persephacin B was very similar to 
persephacin A. When comparing the HSQC, three distinct differences can be observed: the loss 
of a signal at 0.94 (1H) and 18.51 (13C) ppm corresponding to the C-44 carbon of the valine 
residue, the presence of signals at 25.92(13C) and 0.99 (1H) and 1.11 (1H) ppm corresponding to a 
methylene, and new signals at 12.01 (13C) and 0.82 (1H) ppm corresponding to a methyl. The 
mass was determined to have 14 amu units higher than persephacin A. Therefore, persephacin B 
had a substitution of either an isoleucine or a leucine. The alpha proton (H-41) of the altered 
valine residue, remained as a doublet (Figure 26B), which suggested an isoleucine rather than a 
leucine. It has been noted with aureobasidin that the important residue used for exportation was 
the phenylalanine and the important residue for activity was the alpha-hydroxy, therefore it is 
unlikely that the substitution of an isoleucine for a valine would cause a significant effect on 
bioactivity.133 Marfey’s analysis was used to determine the absolute configuration of the 
common amino acids N-Me-Val, Ile, N-Me-Ile, and Leu as N-Me-L-Val, L-Ile, and L-Leu 




 The third analog, persephacin C, was much more hydrophobic than either persephacin A 
or B. While a preparatory HPLC column at 95% acetonitrile caused both persephacin A and B to 
elute within 35 minutes, persephacin C required an extra 20 minutes to elute from the column. 
Upon analysis of the mass spectrum, it was noted that the mass was m/z 16 less than persephacin 
A, suggesting the loss of an oxygen atom.  As can be seen from the 1H NMR spectrum, the two 
methyls of the N-Me-3-OH-Val shifted as singlets at 1.30 and 1.36 ppm to unidentifiable 
splitting at 0.99 ppm and 1.61 ppm (Figure 26). The proton peak of C-53 was shifted upfield 
from 3.80 to 2.86 ppm, which one might expect with the loss of a nearby hydroxy group. In 
addition, a new multiplet appeared at 2.65 ppm which was assigned to C-54, the previously 
quaternary carbon on the N-Me-3-OH-Val residue. Therefore, persephacin C was determined to 
have a substitution of a N-Me-Val in place of the N-Me-3-OH-Val residue. Marfey’s analysis 
was used to determine the absolute configuration of the common amino acids N-Me-Val, Ile, and 





Figure 26: Determination of Persephacin B. The new analog of persephacin B, shifts 
designated in red/yellow in HSQC (A) and red in 1H NMR (B), the signal of the alpha carbon 
which was followed by TOCSY to identify the residue. (C) LCMS shows an increase of 14    





Figure 27 1H NMR Comparison of Persephacin A and Persephacin C. The dotted 
regions show where the designated peaks appear in persephacin A and the solid green 






Figure 28: Productions of Persephacin. Quantification of persephacin over time in different 
media. While less persephacin was produced at 14 days with the higher concentration of 
dehydrated potatoes and dextrose, at 35 days the yields were the highest. Sodium nitrate caused a 
decrease in persephacin production. 
 
5.4.3 Media Optimization and Optimized Isolation 
Due to the slow growing nature of the fungus, media optimization was attempted. A 
concentration curve was generated according to LCMS conditions that could quantify crude 
extracts from each medium. The different media compositions (Figure 28) included increased 
ratios of dehydrated potatoes to dextrose either in a 2:0.6 ratio or a 2:1 ratio. The second 
parameter tested was an increase in the concentration of media components (at a 2:1 ratio), and 
the third parameter tested an additional nitrogen source, NaNO3, would be beneficial to the 




inoculum was taken from a shaken liquid aged 2 weeks in PDB media of 2 g dehydrated potatoes 
with 0.6 g dextrose, and agar inoculum was taken from YM plates. On days 14, 21, 28, and 35, a 
sample of 5 mL was taken aseptically from each condition and extracted with 5 mL ethyl acetate 
3 times. Samples were dissolved in 200 µL before being subjected to chromatography for 
quantification and assessed for metabolite complexity on the LCMS in identical conditions to the 
concentration curve. It was determined that persephacin concentration increased in all media 
over time, suggesting that the fungus does not degrade persephacin after a certain point in the 
time range tested. The inclusion of NaNO3 showed a retardation of growth at all conditions and 
time points. The ratio and the quantity of dehydrated potatoes and dextrose did have a noticeable 
difference on the production of persephacin A. With the same quantity of dehydrated potatoes, 
the ratio of 2:0.6 had increased production over the 2:1 over all time peroids, however after 35 
days, the increased PDB, at 4g dehydrated potatoes and 2g dextrose, surpassed the persephacin A 
concentration of the 2:0.6 ratio. It was determined that PDB +++, 4g dehydrated potatoes and 2g 
dextrose, was determined to yield the greatest amount and that the fungi should be grown for 
about 35 days prior to extraction. Even with the optimized PDB conditions, the yield of 
persephacin A was still low in the shaken flasks. Since endophytes grow among plant tissues, we 
hypothesized that a change in the flask might cause a change in both the surface area and oxygen 
content of the fungal cultures which has been known to influence fungal growth.134,135  Both 





Figure 29. Photo of Roller Bottles. A device that slowly rotates bottles, potentially allowing 
greater surface adhesion of growing organisms. 
 
A roller bottle fermentation (Figure 29) slowly rotates a bottle on its side in an attempt to 
provide a large surface area for cells to adhere to while allowing continual moisture and nutrients 
to reach the cells. Roller bottles with a variety of media (PDB +++ with agar, avocado, PDB+++, 
PDB, PDB+++ with vermiculite, HR-01, and Etched glass with PDB medium) were inoculated 
with equivalent amounts of fungi and grown for 4 weeks. Avocado was chosen as a media 
additive because Spaceloma corylii, has been known to be a pathogenic species of avocado,136 
therefore avocado might provide some nutrients the fungus that were missing in PDB. While 




than the other media, there was no red color and a not as much persephacin production as the 
PDB media which produced the most persephacin A in the 200 mL condition. The PDB+++ 
medium had inconsistent growth between the two flasks, one producing the red pigmentation 
while the other did not. This suggested that persephacin A production is correlated with the red 
pigmentation of the elsinochromes. The fungi grown in the etched flasks, which was a PDB+++ 
media, had increased growth in the 200 mL condition. Ultimately, roller bottles were deemed not 
to be the best conditions for large scale production due to their inconsistencies and not 
substantial increased persephacin production to mitigate the labor involved in prepping and 
cleaning glassware. 
 
Figure 30. Comparative Yield of Persephacin A Respective of Volume. Using baffled flasks, 





Baffled flasks are large plastic flasks with divots in the bottom to increase aeration and 
circulation while mixing (Figure 30). Three different volumes (500mL, 1000mL and 1500mL) 
were tested with proportional inoculum in PDB +++ media were grown for 4 weeks on a shaker 
before being extracted with proportional volumes of ethyl acetate. Persephacin A yields were 
quantified via a calibration curve on the LCMS and were found to be inversely correlated with 
the volume in the flask, which is consistent with the theory that greater amounts of oxygen 
and/or surface area was necessary for the increased production of persephacin A. Since baffled 
flasks did not show a significant increase in persephacin A production, baffled flasks would not 
cause a significant improvement in the fermentation process.  
 
Figure 31: Bioreactor of Spaceloma corylii. A large quantity of medium, 10L, was able to be 




One of the largest limiting factors in the fermentation of persephacin A is the quantity of 
flasks necessary to get a large enough yield of persephacin A, a bioreactor was explored using 10 
L of PDB+++ media and inoculated with 200 mL of a 2 week old Spaceloma corylii culture 
(Figure 31). The bioreactor was covered with aluminum foil to remove light as a variable. A 
bioreactor culture was grown for 4 weeks, and each week 1 L of autoclaved distilled water was 
added to mitigate the loss due to evaporation. Upon extraction, and analysis via LCMS, it an 
esimated yield of 89 mg of persephacin A was expected to be obtained from the single 
bioreactor. A bioreactor of PDB+++ media, with a 4 week growth time was the optimized 
growth conditions for the production of persephacin A.  
  
5.4.4 Bioactivity 
 Persephacin A-C were tested against a panel of fungal species that are known to be plant 
pathogens using fludioxonil,137 a non-systematic fungicide used for agriculture purposes, as a 
positive control. The MIC, minimum inhibitory concentration or the amount required to reduced 
75% of growth, and the MFC, minimum fungicidal concentration or the amount required to 
reduce 100% of growth, were determined against the 8 different isolates: Alternaria brassicicola, 
Alternaria brassicae, Alternaria Tennuissiema, Fusarium oxysporum, Fusarium tricinctum, 
Mycosphaerella populorum, Nodulosporium spp, and Pfaffia gloerata. In all cases, persephacin 
C did not achieve complete or even 75% inhibition in the tested ranges of 0.32 µM to 10 µM. 
This is consistent with published data on aureobasidins, a similar cyclic peptide also with a 3-OH 
valine, that lost activity after synthetic modifications attached long chain aliphatic residues.133 
Percephacin B had lower MIC values than persephacin A for all fungi except the M. populorium 




neither compound showed MIC or MFC activity in the designated range. The fludioxonil was 
more potent than the peptides, with lower MIC except in the cases of F. oxysporum where it 
matched persephacin A and persephacin B had a lower MIC (1.25 µM versus 5 µM), and P. 
glomerata where fludioxonil had no activity in the range tested whereas both persephacin A and 
B had low MIC (0.625, 1.25) and MFC (1.25, 5) values.  
 
Table 2: MIC and MFC Values of Persephacin A-C and Fluidioxonil Against Possible 
Phytopathogenic (Endophytic) Fungi. MIC is the minimum inhibitory concentration or the 
amount required to reduced 75% of growth, and MFC is the minimum fungicidal concentration 
























A. brassicicola 5 20 2.5 ≥20 ≥20 ≥20 1.25 ≥20 
A. brassicae 1.25 2.5 0.625 1.25 ≥20 ≥20 0.625 2.5 
A. tennuissiema 10 10 2.5 2.5 ≥20 ≥20 1.25 1.25 
Fusarium oxysporum 5 20 1.25 20 ≥20 ≥20 5 ≥20 
F. tricinctum 5 10 2.5 ≥20 ≥20 ≥20 1.25 ≥20 
M. populorum 2.5 10 5 ≥20 ≥20 ≥20 1.25 ≥20 
Nodulosporium spp. ≥20 ≥20 ≥20 ≥20 ≥20 ≥20 0.625 ≥20 






5.4.5 Systemicity and Infiltration Studies 
 The activity of persephacin A was evaluated in plants and its systemicity was also 
analyzed to determine if it was suitable for an agricultural fungicide and if so, what type of 
application might be necessary.137 Depending on the mobility of a compound within a plant (i.e., 
xylem mobile, phloem mobile, and nonmobile) a fungicide can be applied to treat certain 
conditions. The xylem flow brings nutrition from the roots to the leaves and therefore would 
cause compounds to extend out from the point of contact. A spray application on the leaves, 
would not allow antifungal activity against root pathogens. For this, phloem mobility would be 
important which is typically used for transportation of sugars and works in a diffusion mediated 
fashion (Figure 32). 
 
Figure 32: Different Types of Compound Mobility If a compound is xylem mobile it will 
move outward from the application location. If a compound is phloem mobile is will move both 
outwards and inwards and should therefore be seen everywhere in the plant. A non-mobile 





 To test the mobility, an emulsifiable concentrate was created using DMSO as both the 
penetrant and solvent for mobility testing. While DMSO might not be applicable in the 
agricultural field due to its propensity for shuttling compounds through tissue in humans, using it 
in this instance would ensure penetration into plant tissues to measure general mobility.138 
Vehicle control and the xylem mobile compound azoxystrobin were used on two leaf stage 
cabbage plants.139 The leaf on which the compound was applied was segmented into three 
different parts: distal, application zone, and inner. The rest of the plant was segmented into 
petiole of the leave with the compound applied, the new leaf, stem, and roots. After extraction 
with MeOH, compounds were analyzed by the LCMS with selected mass and had a detection 
limit of <1 µg/mL. 
 The azoxystrobin was seen in two of the segments: the application zone on the leaf and 
the distal end of the same leaf. As the azoxystrobin has been noted to be xylem mobile, this 
confirmed the assay as able to detect mobility. Persephacin A was only identified in the 
application zone of the original leaf and was therefore determined to be not mobile at detectable 
levels within the plant.  
While working with the compound, it became insoluble at higher concentrations of water 
which might explain the lack of mobility within the plant, however, there was a noticeable 
inhibition zone around the major colony of Sephacaloma corylii as it grew on agar which 
suggested that there might be some ability of the compound to be mobile in the right media. With 
the currently tested emulsifiable concentrate, the compound would be best suited for preventative 




Infiltration Assay.  
 
Figure 33. Infiltration Assay of Emulsifiable Concentrate of Azoxystrobin Control and 
Persephacin A. 
After application of an emulsifiable concentrate(azoxystrobin control, persephacin A), different 
segments (Bottom, Middle and Distal of the leaf, petiole, new leaf, stem and roots) were 
extracted and analyzed via LC-MS. Azoxystrobin ions were observed in the distal and middle 
regions of the original leaf, while persephacin A ions were only observed in the middle region of 







 Two new bioactive compounds were isolated and termed persephacin A and B and a third 
inactive analogue termed persephacin C. These new compounds share structural similarities with 
the known class of cyclic peptides aureobasidins, however, in place of the phenylalanines of the 
aureobasidins, the persephacins have a new long aliphatic chain amino acid herein termed 
persephanine. This new aliphatic residue is thought to negate the efflux mechanism in fungi. 
Further research will need to be conducted to determine the susceptibility of compounds to such 
mechanisms.  
These compounds were tested against 8 different suspected pathogens and had low µM 
MIC values against 7 of them. Mobility studies in cabbage plants suggested the compound does 
not exhibit systematic distribution and would therefore need to be applied as a topical 
agricultural fungicide. For a topical fungicide photodegradation studies would be necessary, but 




5.6.1 Fungus Isolation and Identification 
 The fungus was isolated from the heathy leaf of a poplar (Populus nigra) tree, collected 
in Oklahoma, USA. The plant samples were collected in zip-loc bags and stored at 4°C until 
processed. Leaf samples were thoroughly washed with mild soap and distilled water to clean the 
surface. Samples were then surface-disinfected by soaking in 95% Ethanol (Pharmco-AAPER, 
USA) for 10 seconds, in 10% bleach (Great Value, Wal-Mart, Inc., USA REF: 550655043) for 2 




for 30 seconds and dried with sterilized paper towel before being processed for the isolation of 
endophytes by a laser into a 96-well plate containing CMAD (Corn Meal Agar + 1% Dextrose) 
media. The 96-well plate was incubated at ambient daylight and 22–24 °C for four weeks. The 
fungi were purified by single hyphal tip isolation onto CMAD small Petri plates and this was 
repeated three times. The pure culture was transferred to 20% glycerol for cryopreservation for 
further use.  Finally, the fungus was identified using cultural characteristics, morphology and ITS 
sequencing (ITS1 primer: 5’- CTTGGTCATTTAGAGGAAGTAA-3’ and ITS4 primer: 5’-
TCCTCCGCTTATTGATATGC-3’). 
 
5.6.2 Compound Isolation 
 The Sphaceloma coryli was grown in PDB media (2 g dehydrated potato flakes and 0.6g 
dextrose in 200 mL) in 15 shaken glass Erlenmeyer flasks. The slow-growing fungus was grown 
for 4 weeks and extracted with ethyl acetate to yield 1.3 g. The crude extract was subjected to 
bioassay guided fractionation on a VLC HP20ss column using a stepwise gradient of MeOH in 
H2O (30%, 50%, 70%, 90%, 100% and 50% MeOH in DCM). The resulting 90% MeOH in H2O 
fraction (240 mg) was subjected to a preparatory C18 HPLC column at 55% MeCN in H2O to 
give 21 mg of elsinochrome D. The 100% MeOH fraction (356mg) was further subjected to 
chromatography on C18 prep HPLC with a 40-100% MeCN in H2O with 0.1% formic acid as a 
gradient over 15 minutes to yield 8 fractions. Elsinochromes A (1.0 mg) and E (3.4 mg) were 
identified from these fractions and further purified using a semiprep biphenyl column at 40% 
MeCN in H2O with 0.1% formic acid. Persephacin A was also identified from the 8 fractions, but 




95% MeCN in H2O and a biphenyl column (kinentex 5 µm biphenyl 100Å, 250x100mm) at 65% 
MeCN in H2O with 0.1% formic acid to yield 3 mg.  
 
5.6.3 Media Optimization  
Due to the slow growing nature of the fungus, media optimization was attempted. A 
concentration curve (0.01 mg/mL to 1 mg/mL) and LCMS conditions (95% ACN and 5% 0.1% 
TFA in H2O isocratic,) were chosen to quantify crude extracts from each media analyzed. The 
different media compositions included increased ratios of dehydrated potatoes to dextrose either 
in a 2:0.6 ratio or a 2:1 ratio. The second parameters tested, was an increase in the concentration 
of media components (at a 2:1 ratio), and the third parameter tested was if the extra presence of a 
nitrogen source, NaNO3, would be beneficial to the production of persephacin. A final 
parameter, the inoculum, was tested. Broth inoculum was taken from a shaken liquid aged 2 
weeks in PDB media of 2 g dehydrated potatoes with 0.6g dextrose, and agar inoculum was 
taken from YM plates. On days 14, 21, 28, and 35, a sample of 5 mL was taken aseptically from 
each condition and extracted with 5mL ethyl acetate 3 times. Samples were dissolved in 200 µL 
before being subjected to chromatography for quantification and assessed for metabolite 
complexity on the LCMS in identical conditions to the concentration curve.  
Baffled flask and roller bottles were each grown for 4 weeks prior to extraction with ethyl 
acetate and comparison of persephacin A in 20 mg/mL of crude extract in MeOH via LCMS and 
calibration curve. Media for baffled flasks was PDB +++, and media for the roller bottles were 
PDB +++, PDB +++ with 0.05% agar, PDB +++ with 6 g avocado per liter, PDB+++ on etched 
glass, PDB+++ with 1.5 g of vermiculite per 100mL media, and HR-01 media. Flasks were 




For the bioreactor condition, 10L of PDB+++ media was inoculated with 200 mL of a 2 
week of Spaceloma corylii culture and grown for 4 weeks. Every week, 1L distilled and 
autoclaved water was added to account for that lost due to the high air flow. Because the 
Sphaceloma coryli mycelium formed small hard balls that were unable to be properly 
homogenized, the mycelia were separated from the broth using linen and was extracted with 
methanol while the broth was partitioned using ethyl acetate.  Both portions were combined, 
suspended at a concentration of 20 mg/mL, and quantified via LCMS. An estimated yield of 89 
mg of Persephacin A was calculated from LCMS and the calibration curve. 
 
5.6.4 Optimized Isolation 
Optimized growth conditions were chosen using an increase in the concentration of the 
mashed potato and sugar in the glass Erlenmeyer flasks (4g dehydrated potato flakes and 2 g 
dextrose per 200 mL). The broth was partitioned with ethyl acetate and the mycelium was 
filtered with linin and then extracted with methanol. When recombined, the extract yielded 25 g 
from 70 flasks. This extract was subjected to a step-gradient HP20ss VLC column with the 4 
stepwise fractions: 70% MeOH in H2O, 90% MeOH in H2O, 100% MeOH in H2O, and 50% 
MeOH in DCM. Both the 90% and 100% MeOH in H2O fractions (totaling 3.5 g) were applied 
to a Sephadex gravity column in MeOH with the fractions monitored by LCMS and yielded a 
total of ~500 mg in the active fraction (<50 mg eluted before the active fraction and ~3 g eluted 
after the active fraction). The fractions were then subjected to C18 preparatory HPLC 
(Shimadzu, Gemini C18 column - 250 mm x 10.1mm, 5µm, Phenomenex) at 95% MeCN in H2O. 
A final separation using a preparatory HPLC biphenyl column  at 90% MeOH in H2O yielded as 




separated using either preparatory or semi-preparatory biphenyl columns to yield persephacins 
B-C. 
5.6.5 Structure Elucidation 
 Bond-line structures were determined through 1H, HSQC, HMBC, TOCSY (NMRS 500 
MHz with a triplet resonance indirect detect probe) and 13C NMR (NMRS 400 MHz dual-
broadband probe). Accurate mass data were acquired using Agilent 6538 high-mass-resolution 
QTOF mass spectrometer. 
Absolute configurations of the proteogenic amino acids were determined by compound 
hydrolysis followed by Marfey’s reaction.140 Hydrolysis was completed on 1 mg of persephacin 
sample in 20% HCl at 100°C for 24 hours. Samples were then dried under nitrogen, and further 
dried in vacuo to remove any residual acid. 40 µl of 1 M NaHCO3 was added to each vial 
followed by 200 µL of 1% FDAA (1-fluoro-2-4-dinitrophenyl-5-L-alanine amide) in acetone. 
The samples were heated for 1 hour at 70°C. Samples were dried under nitrogen, dissolved in 
200 µL of 90% MeOH, and subjected to HPLC analysis (Shimadzu, Kinetex C18 column – 3.0 
mm x 75 mm, 2.6 µm, Phenomenex). 
  
5.6.6 Screening of Antagonistic Activity Against Peyronellaea glomerate (Bio-assay guided 
fractionation – see supplemental) 
 Preliminary screening of test substance (crude, fractions and pure compound) inhibition 
was determined by using a method, described as a Poison Food Technique141 and the inhibition 
to the mycelial growth of fungi was assayed. Briefly, mycelial disks of test fungi (5 mm in 
diameter) removed from the margins of a 7 day-old culture and were transferred to the center of 




Control plates containing media mixed with sterile water (10%, v/v) were included.  Three 
replicates were used per treatment. For each concentration, inhibition of radial growth compared 
with the untreated control was calculated after 5 and 10 days of incubation at 23 °C, in the 12 
hours dark phase. The percentage of growth inhibition (I) was calculated using the formula: I (%) 
=[(C-T)/C] X 100.  Where C and T are the diameter of control fungus and test fungus 
respectively. 
 
5.6.7 Peptide Infiltration Assay 
 There are different application methods for agricultural antifungal compounds. The 
mobility of the compound within the plant tissues determines the appropriate application 
methodology.142 A xylem and phloem mobile compound can be sprays anywhere on the plant 
and can easily treat current infections.142 Compounds that are only xylem mobile need to be 
administered into the soil and compounds that are phloem mobile need to be administered on the 
leaves.142 By using an infiltration assay, where the compound is forced into leaf tissues via 
osmotic pressure, mobility of persephacin A can be traced via LCMS. For this experiment 
cabbage (Brassica olaracea) plants were used. The upper surfaces of two leaves of each plant 
used for assay were marked by drawing lines across the leaf with a marker (Sharpie ultra fine 
point permanent marker). Two concentrations, 1 and 2 μL of persephacin C (2 mM stock 
DMSO) diluted in 98 μl of H2O, were loaded into a syringe and pressed against the leaves at 
increased pressure to maximize compound penetration. Leaves were harvested after 24 hours and 
divided into 3 portions: the application zone, the petiole end, and the distal end. Each sample was 
crushed and extracted 3 times with 5 mL of MeOH. Samples were concentrated in vacuo, 




the LC-MS at 10-100% acetonitrile in 0.1% formic acid and the selected mass chromatogram 
was analyzed and compared to a calibration curve determined with stock persephacin A 
concentrations of 0.5, 1.0, 1.5 and 2.0 mg/mL 
 
5.6.7 Determination of MIC and MFC Against Possible Pathogenic Fungi 
 The MIC and MFC of persephacins A-C were determined against 8 phytophathogenic 
(endophytic) fungi. MIC analysis in 96 well plates with a 200 µL inoculum suspension in RPMI-
1640 + MOPS with 4 µL of the tested compound at appropriate concentration. MIC 
concentrations ranged from 0.675 to 20 µM and incubated for 24 hours before being analyzed in 
the Operetta. Following analysis, 20 µL of MIC assay were plated on PDA plates to test MFC 






1. Williams, D. H., Stone, M. J., Hauck, P. R. & Rahman, S. K. Why Are Secondary 
Metabolites (Natural Products) Biosynthesized? J. Nat. Prod. 52, 1189–1208 (1989). doi: 
10.1002/hlca.19760590412 
2. Geske, G. D., Wezeman, R. J., Siegel, A. P. & Blackwell, H. E. Small Molecule Inhibitors 
of Bacterial Quorum Sensing and Biofilm Formation. J. Am. Chem. Soc. 127, 12762–
12763 (2005). doi: 10.1002/hlca.19760590412 
3. Veitch, G. E., Beckmann, E., Burke, B. A Relay Route for the Synthesis of Azadirachtin. 
Angew. Chemie Int. Ed. 46, 7633–7635 (2007). doi: 10.1002/hlca.19760590412 
4. Rüegger, A., Kuhn, M., Lichti, H., Loosli, H., Huguenin, R., Quiquerez, C. von Wartburg, 
A. Cyclosporin A, ein Immunsuppressiv Wirksamer Peptidmetabolit aus Trichoderma 
polysporum (L INK ex P ERS .) Rifai. Helv. Chim. Acta 59, 1075–1092 (1976). doi: 
10.1002/hlca.19760590412 
5. Nibbs, A. E., Montgomery, T. D., Zhu, Y. & Rawal, V. H. Access to Spirocyclized 
Oxindoles and Indolenines via Palladium-Catalyzed Cascade Reactions of Propargyl 
Carbonates with 2-Oxotryptamines and Tryptamines. J. Org. Chem. 80(10) 4928-4941 
(2015). doi:10.1021/acs.joc.5b00277 
6. Eloe-Fadrosh, E. A., Rasko, D. A. The Human Microbiome: From Symbiosis to 
Pathogenesis. Annu. Rev. Med. 64, 145–163 (2013). doi: 10.1002/hlca.19760590412 
7. Pearson, L.; Mihali, T.; Moffitt, M.; Kellmann, R.; Neilan, B. On the Chemistry, 
Toxicology and Genetics of the Cyanobacterial toxins, Microcystin, Nodularin, Saxitoxin 
and Cylindrospermopsin. Marine Drugs 8(5) 1650-1680  (2010). doi:10.3390/md8051650 




Silent Gene Clusters. Fungal Genet. Biol. 48, 15–22 (2011). doi: 
10.1016/j.fgb.2010.04.004 
9. Teichert, I., Nowrousian, M., Pöggeler, S., Kück, U. The Filamentous Fungus Sordaria 
macrospora as a Genetic Model to Study Fruiting Body Development. Advances in 
Genetics (87) 199–244 (2014). doi:10.1016/B978-0-12-800149-3.00004-4 
10. Spiteller, P. Chemical Ecology of Fungi. Nat. Prod. Rep. 32, 971–993 (2015). doi: 
10.1039/C4NP00166D 
11. Riddle, J. M., Contraception and Abortion from the Ancient World to the Renaissance 
Harvard University Press (1994). 
12. Buenz, E. J. Drug Discovery from Historic Herbal Texts. Computer Applications in 
Pharmaceutical Research and Development 103–120 (2006). 
doi:10.1002/0470037237.ch4 
13. Amin, O. S. M. Coin from Cyrene Showing Silphium Plant. (2016). Unaltered. 
https://www.ancient.eu/image/5893/coin-from-cyrene-showing-silphium-plant/ License: 
https://creativecommons.org/licenses/by-nc-sa/3.0/legalcode 
14. Baty, K. Cyrene Coin. Celator 9, 6–8 (1995). access through wikimedia commons under 
fair use. 
15. Ikeda, K., Arao, Y., Otsuka, H., Nomoto, S., Horiguchi, H., Kayama, F., Ikeda, K., Kato, 
S., Kayama, F., Kato, S. Terpenoids Found in the Umbelliferae Family Act as 
Agonists/Antagonists for ERα and ERβ: Differential Transcription Activity between 
Ferutinine-Liganded ERα and ERβ. Biochem. Biophys. Res. Commun. 291, 354–360 
(2002). doi: 10.1006/bbrc.2002.6446 




Toxicol. 41, 235–239 (2003). doi: 10.1081/CLT-120021104 
17. Trichopoulou, A. Traditional Mediterranean Diet and Longevity in the Elderly: a Review. 
Public Health Nutr. 7, 943–947 (2004). doi: 10.1079/PHN2004558 
18. Masarovičová, E., Kráľová, K. Medicinal Plants - Past, Nowadays, Future. Acta Hortic. 
749 19–27 (2007). doi:10.17660/ActaHortic.2007.749.1 
19. Lavoisier, A. Encyclopedia of Modern Europe: Europe 1789-1914: Encyclopedia of the 
Age of Industry and Empire, Charles Scribner & Sons, 1, 2006 
20. Toledo-Pereyra, L. Medical Renaissance. J. Investig. Surg. 28, 127–130 (2015). 
21. Sneader, W. Drug Discovery: The Evolution of Modern Medicines. Wiley, 1 (1985). 
22. Scheindlin, S. The Timeline: A Brief History of Pharmacology. Mod. Drug Discov. 4, 87–
88, 91 (2001). 
23. Demain, A. L., Sanchez, S. Microbial Drug Discovery: 80 Years of Progress. J. Antibiot. 
(Tokyo). 62, 5–16 (2009). doi: 10.1038/ja.2008.16 
24. Tan, S. & Tatsumura, Y. Alexander Fleming (1881–1955): Discoverer of Penicillin. 
Singapore Med. J. 56, 366–367 (2015). doi: 10.1038/ja.2008.16 
25. Alexander Flemming, New World Encyclopedia, last modified 28 February 2019, 
http://www.newworldencyclopedia.org/entry/Alexander_Fleming accessed 02 July 2019 
26. Lobanovska, M.; Giulia, P. Penicillin’s Discovery and Antibiotic Resistance: Lessons for 
the Future? Yale J. Biol. Med. 90, 135–145 (2017). 
27. Ganesan, A. The Impact of Natural Products Upon Modern Drug Discovery. Curr. Opin. 
Chem. Biol. 12, 306–317 (2008). doi: 10.1016/j.cbpa.2008.03.016 
28. Singla, A. K., Garg, A., Aggarwal, D. Paclitaxel and its Formulations. Int. J. Pharm. 235, 




29. Naidu, R. Semi-Synthetic Process for the Preparation of Taxane Derivatives. Patent 
US8299279B2 (2012). 
30. Damen, E. W. P., Wiegerinch, P. H. G., Braamer, L., Sperling, D., de Vos, D., Scheeren, 
H. W.  Paclitaxel Esters of Malic Acid as Prodrugs with Improved Water Solubility. 
Bioorg. Med. Chem. 8, 427–432 (2000). doi: 10.1016/S0968-0896(99)00301-6 
31. Feng, X.; Zhou, Z.; Cui, Y. Semisynthesis of Paclitaxel. Patent CN2013-10082108 (2013). 
32. Gong, X.; Gao, J.; Zhou, L.; Yang, B.; Liang, P.; Lu, Y.; Wang, Q.; Yu, Q. Semi-synthetic 
Method for Preparation of Paclitaxel. Patent CH103450118 (2013). 
33. Mountford, P. G. The Taxol® Story - Development of a Green Synthesis via Plant Cell 
Fermentation. Green Chemistry in the Pharmaceutical Industry Wley-VCH Verlag GmbH 
& Co. (2010). doi:10.1002/9783527629688.ch7 
34. Presidential Green Chemistry Challenge: 2004 Greener Synthetic Pathways Award., EPA 
(2004) Accessed via https://www.epa.gov/greenchemistry/presidential-green-chemistry-
challenge-2004-greener-synthetic-pathways-award on 02 July 2019 
35. Webb, T. R. the Scope of the Role of Medicinal Chemists in Drug Discovery. ACS Med. 
Chem. Lett. 9 (12), 1153–1155 (2018). doi: 10.1021/acsmedchemlett.8b00548 
36. Schenone, M., Wagner, B. K., Clemons, P. A., Program, B. Target Identification and 
Mechanism of Action in Chemical Biology and Drug Discovery. Nat Chem Biol 9, 232–
240 (2017). doi 10.1038/nchembio.1199.Target 
37. Mehta, D., Jackson, R., Gaurav, P., Jiong, S., Sabbagh, M. Why Do Trials for Alzheimer’s 
Disease Drugs Keep Failing? A Discontinued Drug Perspective for 2010-2015. Expert 
Opin Investig Drugs. 26, 735–739 (2018). 10.1080/13543784.2017.1323868.Why 




Clerici, M., Cosby, S., Del Tredici, K., Field, H., Fulop, T., Grassi, C., Griffin, W., Haas, 
J., Hudson, A.,  Kamer, A., Kell, D., Licastro, F., Letenneur, L., Loyheim, H., Mancuso, 
R., Miklossy, J., Otth, C.,  Palamara, A. T., Perry, G., Preston, C., Pretorius, E., 
Strandberg, T., Tabet, N., Taylor-robinson, S., Whittum-Hudson, J. Microbes and 
Alzheimer’s Disease. J. Alzheimer’s Dis. 51, 979–984 (2016). doi: 10.3233/JAD-160152 
39. Lapinski, C.; Lombardo, F.; Dominy, P.; Feeney, P. Experimental and Computational 
Approaches to Estimate Solubility and Permeability in Drug Discovery and Development 
Settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001). 
40. Li, J.; Vederas, J. Drug Discovery and Natural Products: End of an Era or an Endless 
Frontier? Science (80-. ). 325, 161–165 (2009). 
41. Beutler, J. A. Natural Products as a Foundation for Drug Discovery. in Current Protocols 
in Pharmacology 1–30, John Wiley & Sons, Inc., (2009). 
doi:10.1002/0471141755.ph0911s46 
42. Camp, D.; Davis, R.; Campitelli, M.; Ebdon, J.; Quinn, R. Drug-like Properties: Guiding 
Principles for the Design of Natural Product Libraries. J. Nat. Prod. 75 (1), 72–81 (2012). 
43. Harvey, A.; Edrada-Ebel, R.; Quinn, R. The Re-Emergences of Natural Products for Drug 
Discovery in Genomics Era. Discov, Nat Rev Drug 14, 111–129 (2015). 
44. Barnes, E. C., Kumar, R. & Davis, R. A. The Use of Isolated Natural Products as 
Scaffolds for the Generation of Chemically Diverse Screening Libraries for Drug 
Discovery. Nat. Prod. Rep. 33, 372–381 (2016). doi: 10.1039/C5NP00121H 
45. Gerwick, B. C., Sparks, T. C. Natural Products for Pest Control: an Analysis of their Role, 
Value and Future. Pest Manag. Sci. 70, 1169–1185 (2014). doi: 10.1002/ps.3744 




Prod. Rep. 31, 1425–1448 (2014). doi: 10.1039/c4np00060a 
47. Richards, T. A., Jones, M. D. M., Leonard, G. & Bass, D. Marine Fungi: Their Ecology 
and Molecular Diversity. Ann. Rev. Mar. Sci. 4, 495–522 (2012). doi: 10.1146/annurev-
marine-120710-100802 
48. Li, G., Lou, H. X. Strategies to Diversify Natural Products for Drug Discovery. Med. Res. 
Rev. 38, 1255–1294 (2018). doi: 10.1002/med.21474 
49. Strobel, G., Daisy, B. Bioprospecting for Microbial Endophytes and their Natural 
Products. Microbiol. Mol. Biol. Rev. 67, 491–502 (2003). 10.1128/MMBR.67.4.491–
502.2003 
50. Denning, D. W., Bromley, M. J. How to Bolster the Antifungal Pipeline. Science. 347, 
1414–1416 (2015). doi: 10.1126/science.aaa6097 
51. Yu, H., Zhang, L., Li, L., Zeng, C., Guo, L., Li, W., Sun, P., Qin, L. Recent Developments 
and Future Prospects of Antimicrobial Metabolites Produced by Endophytes. Microbiol. 
Res. 165, 437–449 (2010). doi: 10.1016/j.micres.2009.11.009 
52. Ikeda, H., Fukuda, T., Yokoyama, J. Endophytic Fungi Associated with a Holoparasitic 
Plant, Balanophora japonica; (Balanophoraceae). Am. J. Plant Sci. 07, 152–158 (2016). 
doi: 10.4236/ajps.2016.71016 
53. Schulz, B., Boyle, C., Draeger, S., Römmert, A.-K., Krohn, K. Endophytic Fungi: a 
Source of Novel Biologically Active Secondary Metabolites. Mycol. Res. 106, 996–1004 
(2002). doi: 10.1017/S0953756202006342 
54. Pedrosa, F. O., Monteiro, R. A., Wassem, R., Cruz, L., Ayub, R., Colauto, N., Fernandez, 
M. A., Fungaro, M., Grisard, E., Hungria, M., Madeira, H., Nodari, R., Osaku, C., Petzl-




L., Marin, A., Araujo, L., Balsanelli, E., Baura, V., Chubatsu, L., Faoro, H., Favetti, A,. 
Friedermann, G., Glienke, C., Karp, S., Kava-Cordeiro, V., Raittz, R., Ramos, H., Ribeiro, 
E., Rigo, L., Rocha, S., Schwab, S., Silva, A., Souza, E., Tadrea-Sfeir, Torres, R., Dabul, 
A., Soares, M., Gasque, L., Gimenes, C., Valle, J., Ciferi, R., Corea, L., Murace, N., 
Pamphile, J., Patussi, E., Prioli, A., Prioli, S., Rocha, C., Arantes, O., Furlaneto, M., 
Godoy, L., Oliveria, C., Satori, D., Vilas-Boas, L., Watanabe, M., Dambros, B., Guerra, 
M., Mathioni, S., Santos, K., Steindel, M., Vernal, J., Barcellos, F., Campo, R., Chueire, 
L., Nicolas, M., Pereira-Ferrari, L, da Conceicao, S., Gioppo, N., Margarido, V., Menck-
Soares, M., Pinto, F., Simao, R., Takahashi, E., Yates, M., Souza, E. Genome of 
Herbaspirillum Seropedicae Strain SmR1, a Specialized Diazotrophic Endophyte of 
Tropical Grasses. PLoS Genet. 7 (5), (2011). doi:10.1371/journal.pgen.1002064 
55. Luo, S., Xu, T., Chen, L., Chen, J., Rao, C., Xiao, X., Wan, Y., Zeng, G., Long, F., Liu, 
C., Liu, Y. Endophyte-Assisted Promotion of Biomass Production and Metal-Uptake of 
Energy Crop Sweet Sorghum by Plant-Growth-Promoting Endophyte Bacillus sp. SLS18. 
Appl. Microbiol. Biotechnol. 93, 1745–1753 (2012). doi: 10.1007/s00253-011-3483-0 
56. Ye, Y., Takada, T., Buchwald, S. L. Palladium-Catalyzed Fluorination of Cyclic Vinyl 
Triflates: Effect of TESCF 3 as an Additive. Angew. Chemie Int. Ed. 55, 15559–15563 
(2016). doi: 10.1002/anie.201608927 
57. Novel Drugs 2015 Summary. Acessed by: 
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UC
M485053.pdf.  
58. Mak, I. W., Evaniew, N., Ghert, M. Lost in Translation: Animal Models and Clinical 




59. Combes, R., Berridge, T., Connelly, J., Eve, M., Garner, R., Toon, S., Wilcox, P. Early 
Microdose Drug Studies in Human Volunteers Can Minimise Animal Testing: 
Proceedings of a Workshop Organised by Volunteers in Research and Testing. Eur. J. 
Pharm. Sci. 19, 1–11 (2003). 
60. Hoffmann-La Roche Ltd. Growing Human Organs-on-a-Chip. (2019). Available at: 
https://www.roche.com/research_and_development/what_we_are_working_on/research_t
echnologies/organs-on-a-chip-technology.htm.  
61. Kaur, G. Dufour, J. M. Cell Lines. Spermatogenesis 2, 1–5 (2012). 
62. Begley, C. G., Ellis, L. M. Raise Standards for Preclinical Cancer Research. Nature 483, 
531–533 (2012). 
63. Wang, B., Park, E., King, J., Mattes, A., Nimmo, S., Clendinen, C., Edison, A., Anklin, 
C., Cichewicz, R. Transferring Fungi to a Deuterium-Enriched Medium Results in 
Assorted, Conditional Changes in Secondary Metabolite Production. J. Nat. Prod. 78, 
1415–1421 (2015). 
64. Asao, T., Buchi, G., Abdel-Kader, M., Chang, S., Wick, E., Wogan, G. The Structures of 
Aflatoxins B and G 1. J. Am. Chem. Soc. 87, 882–886 (1965). 
65. Eaton, D. L., Gallagher, E. P. Mechanisms of Aflatoxin Carcinogenesis. Annu. Rev. 
Pharmacol. Toxicol. 34, 135–172 (1994). 
66. Mattes, A. O., Russell, D., Tishchenko, E., Liu, Y., Cichewicz, R., Robinson, S. 
Application of 19 F Quantitative NMR to Pharmaceutical Analysis. Concepts Magn. 
Reson. Part A 45A, e21422 (2016). 
67. Pauli, G. F.; Jaki, B. U.; Lankin, D. C. Quantitative 1H NMR: Development and Potential 




68. Bharti, S. K.; Roy, R. Quantitative 1H NMR Spectroscopy. TrAC, Trends Anal. Chem 35, 
5–26 (2012). 
69. Griffiths, L. Assay by Nuclear Magnetic Resonance Spectroscopy: Quantification Limits. 
Anal. (Cambridge, U. K.) 123, 1061–1068 (1998). 
70. Dolbier, W. R. Guide to Fluorine NMR for Organic Chemists. John Wiley & Sons, Inc., 
2009. 
71. Barry, S. J., Pham, T. N., Borman, P. J., Edwards, A. J., Watson, S. A. A Risk-Based 
Statistical Investigation of the Quantification of Polymorphic Purity of a Pharmaceutical 
Candidate by Solid-State 19F NMR. Anal. Chim. Acta 712, 30–36 (2012). 
72. Do, N. M., Olivier, M. A., Salisbury, J. J., Wager, C. B. Application of Quantitative 19F 
and 1H NMR for Reaction Monitoring and In Situ Yield Determinations for an Early 
Stage Pharmaceutical Candidate. Anal. Chem. 83, 8766–8771 (2011). 
73. Mutlib, A., Espina, R., Atherton, J., Wang, J., Talaat, R., Scatina, J., Chandrasekaran, A. 
Alternate Strategies to Obtain Mass Balance without the Use of Radiolabeled Compounds: 
Application of Quantitative Fluorine (19F) Nuclear Magnetic Resonance (NMR) 
Spectroscopy in Metabolism Studies. Chem. Res. Toxicol. 83, 8766–8771 (2012). 
74. Wider, G., Dreier, L. Measuring Protein Concentrations by NMR Spectroscopy. J. Am. 
Chem. Soc. 128, 2571–2576 (2006). 
75. Dreier, L., Wider, G. Concentration Measurements by PULCON Using X-filtered or 2D 
NMR Spectra. Magn. Reson. Chem. 44, S206–S212 (2006). 
76. Traficante, D. D. Optimum Tip Angle and Relaxation Delay for Quantitative Analysis. 
Concepts Magn. Reson. 4, 153–160 (1992). 




R., Morris, G. A. Increasing the Quantitative Bandwidth of NMR Measurements. Chem. 
Commun. 52, 2916–2919 (2016). 
78. Boehlen, J. M., Burghardt, I., Rey, M., Bodenhausen, G. Frequency-Modulated ‘Chirp’ 
Pulses for Broadband Inversion Recovery in Magnetic Resonance. J. Magn. Reson. 90, 
183–91 (1990). 
79. Malz, F., Jancke, H. Validation of Quantitative NMR. J. Pharm. Biomed. Anal. 38, 813–
823 (2005). 
80. Keeler, J. Understanding NMR Spectroscopy. Wiley (2005) 
81. Weiss, G. H., Ferretti, J. A. Accuracy and Precision in the Estimation of Peak Areas and 
NOE Factors. J. Magn. Reson. 55, 397–407 (1983). 
82. Laatikainen, R., Niemitz, M., Malaisse, W. J., Biesemans, M., Willem, R. A 
Computational Strategy for the Deconvolution of NMR Spectra with Multiplet Structures 
and Constraints: Analysis of Overlapping 13C-2H Multiplets of 13C Enriched Metabolites 
from Cell Suspensions Incubated in Deuterated Media. Magn. Reson. Med. 36, 359–365 
(1996). 
83. Schoenberger, T., Menges, S., Bernstein, M. A., Perez, M., Seoane, F., Sykora, S., Cobas, 
C. Improving the Performance of High-Precision qNMR Measurements by a Double 
Integration Procedure in Practical Cases. Anal. Chem 88, 3836–3843 (2016). 
84. Cobas, C. S., Sykora, S. In Global Spectral Deconvolution (GSD) of 1D0NMR spectra. in 
SMASH (2008). 
85. Sterling, C., Crouch, R., Russell, D. J., Calderon, A. I. 1H-NMR Quantification of Major 
Saccharides in Ac¸ai Raw Materials: a Comparison of the Internal Standard Methodology 




86. Giraudeau, P. Challenges and Perspectives in Quantitative NMR. Magn. Reson. Chem. 55, 
61–69 (2017). 
87. Rahib, L., Smith, B., Aizenberg, R., Rosenzweig, A., Fleshman, J., Matrisian, L. 
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, 
Liver, and Pancreas Cancers in the United States. Cancer Res. 74, 2913–2921 (2014). 
88. Howlader, N., Krapcho, M., Miller, D., Bishop, K., Altekruse, S., Kosary, C., Yu, M., 
Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D., Chen, H., Feuer, E., Cronin, K. SEER 
Cancer Statistics Review, 1975-2013. 
89. Chand, S., O’Hayer, K., Blanco, F. F., Winter, J. M., Brody, J. R. The Landscape of 
Pancreatic Cancer Therapeutic Resistance Mechanisms. Int. J. Biol. Sci. 12, 273–282 
(2016). 
90. Mehlen, P., Puisieux, A. Metastasis: a Question of Life or Death. Nat. Rev. Cancer 6, 
449–458 (2006). 
91. Carter, M.; Shieh, J. Guide to Research Techniques in Neuroscience. Elsevier (2015). 
doi:10.1016/C2013-0-06868-5 
92. Hanahan, D., Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 646–
674 (2011). 
93. Weaver, B. A. How Taxol/Paclitaxel Kills Cancer Cells. Mol. Biol. Cell 25, 2677–2681 
(2014). 
94. Shiau, A. K., Barstad, D., Loria, P., Cheng, L., Kushner, P., Agard, D., Greene, G. The 
Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of this 
Interaction by Tamoxifen. Cell 95, 927–937 (1998). 




Physiological Events in 2D vs. 3D Cell Culture. Physiology 32, 266–277 (2017). 
96. Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., 
Tesei, A. 3D tumor Spheroid Models for in vitro Therapeutic Screening: a Systematic 
Approach to Enhance the Biological Relevance of Data Obtained. Sci. Rep. 6, 19103 
(2016). 
97. Deer, E. L., Gonzalez-Hernandez, J., Coursen, J., Shea, J., Ngatia, J., Scaife, C., Firpo, M., 
Mulvihill, S. Phenotype and Genotype of Pancreatic Cancer Cell Lines. Pancreas 39, 
425–435 (2010). 
98. Prowse, K. R., Greider, C. W. Developmental and Tissue-Specific Regulation of Mouse 
Telomerase and Telomere Length. Proc. Natl. Acad. Sci. 92, 4818–4822 (1995). 
99. Hubbard, K., Ozer, H. L. Mechanism of Immortalization. Age (Omaha). 22, 65–69 (1999). 
100. Lorens, J. B. The Immortality Two-Step. Cell Cycle 14, 798–798 (2015). 
101. Lee, K., Nguyen, C., Ulrich, A., Pour, P., Ouellette, M. Immortalization with Telomerase 
of the Nestin-Positive Cells of the Human Pancreas. Biochem. Biophys. Res. Commun. 
301, 1038–1044 (2003). 
102. Hellwig, V., Mayer-Bartschmid, A., Muller, H., Greif, G., Kleymann, G., Zitzmann, W., 
Tichy, H., Stadler, M. Pochonins A−F, New Antiviral and Antiparasitic Resorcylic Acid 
Lactones from Pochonia chlamydosporia var. c atenulata. J. Nat. Prod. 66, 829–837 
(2003). 
103. Sassa, T., Aoki, H., Namiki, M., Munakata, K. Plant Growth-Promoting Metabolites of 
Sclerotinia sclerotiorum. I. Isolation and Structures of Sclerotinins A and B. Agr. Biol. 
Chem. 32, 1432–9 (1968). 




Fragment Coupling: Siccanol Is Terpestacin, Not 11- e pi -Terpestacin. J. Am. Chem. Soc. 
125, 11514–11515 (2003). 
105. Adachi, H., Doi, H., Kasahara, Y., Sawa, R., Nakajima, K., Kubota, Y., Hosokawa, N., 
Tateishi, K., Nomoto, A. Asteltoxins from the Entomopathogenic Fungus Pochonia 
bulbillosa 8-H-28. J. Nat. Prod. 78, 1730–1734 (2015). 
106. Maruyama, M., Osanawa, H., Sato, S., Sato, T., Takahashi, A., Takeuchi, T., Tamamura, 
T., Texuka, Y. JPH1112280A. (1997). 
107. Stephens, P. J., Devlin, F. J., Cheeseman, J. R., Frisch, M. J. Calculation of Optical 
Rotation Using Density Functional Theory. J. Phys. Chem. A 105, 5356–5371 (2001). 
108. Berova, N., Bari, L., Pescitelli, G. Application of Electronic Circular Dichroism in 
Configurational and Conformational Analysis of Organic Compounds. Chem. Soc. Rev. 
36, 914 (2007). 
109. Menendez, C., Bauer, Z., Huber, H., Gad'on, N., Steter, K., Fuchs, G. Presence of Acetyl 
Coenzyme A (CoA) Carboxylase and Propionyl-CoA Carboxylase in Autotrophic 
Crenarchaeota and Indication for Operation of a 3-Hydroxypropionate Cycle in 
Autotrophic Carbon Fixation. J. Bacteriol. 181, 1088 LP-1098 (1999). 
110. Steyn, P. S., Vleggaar, R. Biosynthesis of Asteltoxin by Cultures of Emericella 
Variecolor. The Role of Propionate in the Biosynthesis and Evidence for a 1,2-Bond 
Migration in the Formation of the Bistetrahydrofuran Moiety. J. Chem. Soc. Chem. 
Commun. 977 (1984). doi:10.1039/c39840000977 
111. Vleggaar, R. Biosynthetic Studies on Some Polyene Mycotoxins. Pure Appl. Chem. 58, 
239–256 (1986). 




Polyketide Biosynthesis. FEMS Microbiol. Lett. 351, 116–125 (2014). 
113. Peña-Morán, O., Villarreal, M., Álvarez-Berber, L., Meneses-Acosta, A., Rodríguez-
López, V. Cytotoxicity, Post-Treatment Recovery, and Selectivity Analysis of Naturally 
Occurring Podophyllotoxins from Bursera fagaroides var. fagaroides on Breast Cancer 
Cell Lines. Molecules 21, 1013 (2016). 
114. Sayood, S. F., Suh, H., Wilcox, C. S., Schuster, S. M. Effect of Citreoviridin and 
Isocitreoviridin on Beef Heart Mitochondrial ATPase. Arch. Biochem. Biophys. 270, 714–
721 (1989). 
115. Scita, G. The Stability of β-Carotene Under Different Laboratory Conditions. J. Nutr. 
Biochem. 3, 124–128 (1992). 
116. Mordi, R. C. Mechanism of Beta-Carotene Degradation. Biochem. J. 292, 310–2 (1993). 
117. Genovese, S., Taddeo, V., Epifano, F., Fiorito, S., Bize, C., Rives, A., de Medina, P. 
Characterization of the Degradation Profile of Umbelliprenin, a Bioactive Prenylated 
Coumarin of a Ferulago Species. J. Nat. Prod. 80, 2424–2431 (2017). 
118. Ravi, M., Ramesh, A., Pattabhi, A. Contributions of 3D Cell Cultures for Cancer 
Research. J. Cell. Physiol. 232, 2679–2697 (2017). 
119. Warcup, J. H. Isolation of Fungi from Hyphæ present in Soil. Nature 175, 953–954 
(1955). 
120. Du, L., King, J. B. & Cichewicz, R. H. Chlorinated Polyketide Obtained from a Daldinia 
sp. Treated with the Epigenetic Modifier Suberoylanilide Hydroxamic Acid. J. Nat. Prod. 
77, 2454–2458 (2014). 
121. Hansen, M. B., Nielsen, S. E., Berg, K. Re-examination and Further Development of a 




Methods 119, 203–210 (1989). 
122. Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., 
Mendiola, M., Hardisson, D., Eccles, S. Advances in Establishment and Analysis of 
Three-Dimensional Tumor Spheroid-Based Functional Assays for Target Validation and 
Drug Evaluation. BMC Biol. 10, 29 (2012). 
123. Minutolo, M.; Nanni, B.; Scala, F.; Alioto, D. Sphaceloma coryli : A Reemerging 
Pathogen Causing Heavy Losses on Hazelnut in Southern Italy. Plant Dis. 100, 548–554 
(2016). 
124. Fan, X. L., Barreto, R., Groenewald, J., Bezerra, J., Pereira, O., Cheewangkoon, R., 
Mostert, L., Tian, C., Crous, P. Phylogeny and Taxonomy of the Scab and Spot 
Anthracnose Fungus Elsinoë (Myriangiales, Dothideomycetes). Stud. Mycol. 87, 1-41 
(2017). doi:10.1016/j.simyco.2017.02.001 
125. Montesinos, E., Bardají, E. Synthetic Antimicrobial Peptides as Agricultural Pesticides for 
Plant-Disease Control. Chem. Biodivers. 5, 1225–1237 (2008). 
126. Royal Botanic Gardens Kew. State of the World’s Plants 2017. Accessed by 
http://stateoftheworldsplants.org/ (2018). 
127. Azevedo, M. M., Faria-Ramos, I., Cruz, L. C., Pina-Vaz, C., Gonçalves Rodrigues, A. 
Genesis of Azole Antifungal Resistance from Agriculture to Clinical Settings. J. Agric. 
Food Chem. 63, 7463–7468 (2015). 
128. Hashida-Okado, T., Ogawa, A., Endo, M., Yasumoto, R., Takesako, K., Kato, I. AUR1, a 
Novel Gene Conferring Aureobasidin Resistance on Saccharomyces cersvisiae: A study of 
Defective Morphologies in Aur1p-Depleted Cells. Mol. Gen. Genet. 251, 236–244 (1996). 




I. Role of ABC Transporters in Aureobasidin A Resistance. Antimicrob. Agents 
Chemother. 42, 755–61 (1998). 
130. Zhang, A., He, L., Gao, J., Xu, X., Li, S., Bai, M., Qin, J. Metabolites from an Endophytic 
Fungus Sphaceloma sp. LN-15 Isolated from the Leaves of Melia azedarach. Lipids 44, 
745–751 (2009). 
131. Kurobane, I., Vining, L. C., McInnes, A. G., Smith, D. G., Walter, J. A. Biosynthesis of 
Elsinochromes C and D. Pattern of Acetate Incorporation Determined by 13 C and 2 H 
NMR. Can. J. Chem. 59, 422–430 (1981). 
132. Hu, J., Sarrami, F., Li, H., Zhang, G., Stubbs, K., Lacey, E., Stewart, S., Karton, A., 
Piggott, A., Chooi, Y. Heterologous Biosynthesis of Elsinochrome A Sheds Light on the 
Formation of the Photosensitive Perylenequinone System. Chem. Sci. 10, 1457–1465 
(2019). 
133. Kurome, T.; Takesako, K.; Kato, O. Aureobasidins as New Inhibitors of P-Glycoprotein in 
Multidrug Resistant Tumor Cells. J. Antibiot. (Tokyo). 51, 353–358 (1998). 
134. Pansuriya, R. C., Singhal, R. S. Response Surface Methodology for Optimization of 
Production of Lovastatin by Solid State Fermentation. Brazilian J. Microbiol. 41, 164–172 
(2010). 
135. Grahl, N., Shepardson, K. M., Chung, D., Cramer, R. A. Hypoxia and Fungal 
Pathogenesis: To Air or Not To Air? Eukaryot. Cell 11, 560–570 (2012). 
136. Hartill, W. F. T. Post-Harvest Diseases of Avocado Fruits in New Zealand. New Zeal. J. 
Crop Hortic. Sci. 19, 297–304 (1991). 
137. Klittich, C. J. R., Green, F. R., Ruiz, J. M., Weglarz, T., Blakeslee, B. A. Assessment of 




138. Barry, B. W. , Pham, T., Borman, P., Edwards, A., Watson, S. Mode of Action of 
Penetration Enhancers in Human Skin. J. Control. Release 6, 85–97 (1987). 
139. Klittich, C. J. R. Fungicide Mobility and the Influence of Physical Properties. in 95–109 
(2014). doi:10.1021/bk-2014-1171.ch005 
140. Bhushan, R., Bruckner, H. Marfey’s Reagent for Chiral Amino Acid Analysis: A Review. 
Amino Acids 27, 231–247 (2004). 
141. Balouiri, M., Sadiki, M., Ibnsouda, S. K. Methods for in vitro Evaluating Antimicrobial 
Activity: A Review. J. Pharm. Anal. 6, 71–79 (2016). 
142. Güell, I., Micalo, L., Cano, L., Badosa, E., Ferre, R., Montesinos, E., Bardaji, L., Planas, 
Marta. Peptidotriazoles with Antimicrobial Activity Against Bacterial and Fungal Plant 






Appendix A: Supplemental Information 
Appendix A.1: Chapter 4 
 
Figure A1: Pochonia suchlasporia Grown on CheeriosTM before being extracted for analysis. 
 
 
A.1.1 Fungus Identification 














A.1.2 General Purification Methods 
 
Figure A2. Isolation Scheme of Compounds from Pochonia suchlasporia. Bioassay guided 
fractionation singled out three sub-fractions which yielded five compounds that were subjected 
to both monolayer and spheroid assays.  
 
 
 Initial isolation was done as presented in the figure. HPLC conditions were optimized for 
purification of the following compounds. Asteltoxin was purified using preparative HPLC 
(Gemeni C18, 110 Å, 250 x 21.2 mm, 10 mL/min) at 55% MeOH for 4 minutes, followed by 55-




preparative HPLC (Gemeni C18, 110 Å, 250 x 21.2 mm, 10 mL/min) at 40-80% over 20 minutes 
of MeOH/H2O. Asteltoxin G was purified by preparative HPLC (Gemeni C18, 110 Å, 250 x 
21.2 mm, 10 mL/min) at 55% MeOH for 4 minutes, folowed by 55-80% over 16 minutes, and a 
wash of 80to100% over 1 minute. A second purification step was required using semipreparative 
HPLC (Gemeni C18, 110 Å, 250 x 21.2 mm, 4 mL/min) at 60% MeOH in  isocratic conditions. 
Sclerotinin A was purified using preparative HPLC (Gemeni C18, 110 Å, 250 x 21.2 mm, 10 
Ml/min) at 40-80% over 20 minutes in MeOH/H2O. (-)Terpestcin was purified by preparative 
HPLC (Gemeni C18, 110 Å, 250 x 21.2 mm, 10 mL/min) at 55% MeOH for 4 minutes, followed 
by 55-80% over 16 minutes, and washed with 80 to 100% over 1 minute. 
 
A.1.3 Spectroscopic Data for AB5529 
  







Polaremetry Data/Optical Rotation measured on Rudolph Research Autopol III automatic 
polarimeter. AB5529 was an orange solid before dilution with MeOH. [α] +28 (c 0.1, MeOH); 
 
 
HRESIMS m/z 403.2109 [M + H]+ (calcd for C23H30O6, 402.2042) 
Figure A4. HRESIMS of AB5529. HRESIMS data was determined on Agilent 6538 QTOF and 




NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 100 and 
125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. Samples dissolved in 
DMSO-d6. 
 















A.1.4 Spectroscopic Data for Asteltoxin 























A.1.5 Spectroscopic Data for Asteltoxin G 
 
 
Polaremetry Data/Optical Rotation measured on Rudolph Research Autopol III automatic 




Figure A11. UV/Vis for Asteltoxin G. UV data was measured by Hewlett Packard 8452A 





Figure A12. HRESIMS of Asteltoxin G. HRESIMS data was determined on Agilent 6538 
QTOF and Agilent 1290 HPLC 
 
HRESIMS m/z 441.1889 [M + Na]+ (calcd for C23H30O7, 418.1992) 
 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 100 and 








































Polaremetry Data/Optical Rotation measured on Rudolph Research Autopol III automatic 
polarimeter. Asteltoxin G was a yellow solid before dilution with MeOH; [α] +32 (c 0.1, MeOH) 
 
 






Figure A19. HRESIMS Data for Sclerotinin A. HRESIMS data was determined on Agilent 
6538 QTOF and Agilent 1290 HPLC 
 
HRESIMS m/z 251.0936 [M - H]- (calcd for C13H16O5, 252.0998)  
 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 100 and 










A.1.7 Spectroscopic Data for (-)-terpestacin 
Polaremetry Data/Optical Rotation measured on Rudolph Research Autopol III automatic 
polarimeter. Asteltoxin G was an off-white solid before dilution with MeOH; [α] -36 (c 0.1, 
MeOH);  
 
Figure A21. HRESIMS data from (-)-terpestacin. HRESIMS data was determined on Agilent 
6538 QTOF and Agilent 1290 HPLC  
 
 
HRESIMS m/z 425.2671 [M + Na]+ (calcd for C25H38O4, 402.2770) 
 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 100 and 
















A.1.8 Degradation of Asteltoxin and Derivatives 
Degradation of Asteltoxin and Derivatives  
 
Figure A24. Degradation of Asteltoxin and Derivatives. 
 
Degradation analysis of the three polyenic alpha-pyrones when exposed to light in 
DMSO. Degradation of asteltoxin was observed within 5 minutes exposure to light, 
while asteltoxin G only showed minimal degradation after 600 minutes. Considering 
degradation was also seen in AB5529 within 15 minutes exposure, the likely increased 
stability arose from the tricyclic furanose motif/decreased conjugation rather than the 






Appendix A.2: Chapter 5 
A.2.1 Fungus Identification of Sephaceloma corylii 
















A.2.2 Initial Isolation Scheme 
 
Figure A25. Initial Isolation Scheme using bioassay guided fractionation. Three 




A.2.3 Optimized Isolation Scheme 
 
Figure A26. Optimized Isolation Scheme. Larger quantities of extract can be more 
easily purified using the following method. 
 
 
A.2.4 Elsinochrome A 
 NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 
100 and 125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. 


















A.2.5 Elsinochrome D 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 
100 and 125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. 
Samples dissolved in dDMSO 
 
  










 A.2.6 Elsinochrome E 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 
100 and 125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. 
Samples dissolved in dDMSO 






















A.2.7 Persephacin A 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 
100 and 125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. 
Samples dissolved in dDMSO 

























A.2.8 Persephacin B 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 
100 and 125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. 
Samples dissolved in dDMSO 
 
  



























A.2.9 Persephacin C 
NMR data were recorded on “Varian VNMR spectrometers (400 and 500 MHz for 1H, 
100 and 125 MHz for 13C) with broad band and triple resonance probes at 25 ±0.5 ˚C. 
Samples dissolved in dDMSO 
 
  
























A.2.10 Media Optimization - Cheerios 
 
Figure A50. Color Difference and Relative Persephacin A Yield 
 
 While growing on Cheerios, a color and morphology change was noticed on 
some areas of the fungus. These were separated, extracted separately and compared for 
persephacin growth. It was determined that persephacin was present in a higher 
concentration when red was also present. 
 
A.2.11 Media Optimization – Roller Bottles 
In an attempt to increase surface area to determine the effect on persephacin 
production, we attempted to grow Spaceloma corylii in roller bottles with either 100mL 




partitioning ethyl acetate. The PDB condition had the greatest yield of persephacin A. 
However the flasks were inconsistent at the 200 mL volume. The agar of the 100 
ml/bottle had the second highest yield. The 100mL flasks had the most consistent yield. 
 










A.2.12 Media Optimization – Bioreactor 
A bioreactor was filled with 10L of PDB+++ media and stirred for 4 weeks. Every 
week, 1L distilled and autoclaved water was added to account for that lost due to the 
high air flow. Upon extraction, and estimated yield of 89 mg of Persephacin A was 
calculated from LCMS and the calibration curve. 
   
Figure A53. Bioreactor and LCMS Chromatograms Showing the 




A.2.13 Bioassay Data – A. brassicicola 
  





























A.2.15 Bioassay Data – N. oryzeae 
 
 




A.2.16 Bioassay Data – C. acutatum 
 













A.2.18 Bioassay Data – P. glomerata  




A.2.19 Marfey’s Analysis 
Figure A60. Marfey's Analysis. Showing the extracted mass Range for persephacins 






Figure A61. Marfey's Analysis. Showing the extracted mass Range for persephacins 
A-C in comparison with standard marfey reagents proline and valine 
